Menu
 
Research menu
Jump to menu

Publications:  Prof Jack Cuzick

Landy R, Sasieni PD, Mathews C, Wiggins CL, Robertson M, McDonald YJ, Goldberg DW, Scarinci IC et al.(2020). Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Int J Cancer vol. 147, (3) 887-896.
10.1002/ijc.32826
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63720
Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, Kronenwett R, Fitzal F et al.(2020). Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. Clin Cancer Res
10.1158/1078-0432.CCR-20-0260
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65634
French DP, Astley S, Astley S, Brentnall AR, Cuzick J, Dobrashian R, Duffy SW, Gorman LS et al.(2020). What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer vol. 20, (1)
10.1186/s12885-020-07054-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65329
Britt KL, Cuzick J, Phillips K-A(2020). Key steps for effective breast cancer prevention. Nat Rev Cancer
10.1038/s41568-020-0266-x
Ramírez-Palacios P, Chen A, Flores YN, Crespi CM, Lazcano-Ponce E, Alvarez-Escobedo D, Torres-Ibarra L, Rivera-Paredez B et al.(2020). Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus-positive women in Mexico. Cancer Cytopathol
10.1002/cncy.22303
Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, Kim J, Poljak M et al.(2020). Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer
10.1038/s41416-020-0920-9
Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, Stoler MH, Ronnett BM et al.(2020). Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Arch Pathol Lab Med vol. 144, (6) 725-734.
10.5858/arpa.2019-0241-OA
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64059
Renehan AG, Pegington M, Harvie MN, Sperrin M, Astley SM, Brentnall AR, Howell A, Cuzick J et al.(2020). Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). British Journal of Cancer vol. 122, (10) 1552-1561.
10.1038/s41416-020-0807-9
Brentnall AR, van Veen EM, Harkness EF, Rafiq S, Byers H, Astley SM, Sampson S, Howell A et al.(2020). A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. International Journal of Cancer vol. 146, (8) 2122-2129.
10.1002/ijc.32541
https://qmro.qmul.ac.uk/xmlui/handle/123456789/59200
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B et al. (2020). 10-year results of the International Breast Cancer Intervention Study II (IBIS-II). BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 527-527.
Hale MJ, Cuzick J, Sestak I (2020). A genome-wide association study of vaginal discharge during tamoxifen therapy for breast cancer prevention. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 570-571.
Buus R, Sestak I, Dowsett M, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, Cuzick J (2020). Correlations between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: a TransATAC study. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 543-543.
Dobson R, Jitlal M, Marshall CR, Noyce AJ, Robson J, Cuzick J, Giovannoni G(2020). Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. Annals of Neurology vol. 87, (4) 599-608.
10.1002/ana.25688
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62858
Sestak I, Kronenwett R, Buus R, Cuzick J, Dowsett M (2020). Prognostic value of EndoPredict and oncotype recurrence score according to patients' age. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 580-580.
Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J (2020). Validation of the Clinical Treatment Score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. BREAST CANCER RESEARCH AND TREATMENT. Conference: UKIBCS vol. 180, 532-533.
Dobson R, Jacobs B, Giovannoni G, Cuzick J(2020). Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors. Multiple Sclerosis Journal
10.1177/1352458520907901
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63739
Cuzick J, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Del Mistro A, Frayle H, Girlando S et al.(2020). Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. Int J Cancer
10.1002/ijc.32973
Brentnall AR, Cuzick J(2020). Risk Models for Breast Cancer and Their Validation. Statistical Science: a review journal vol. 35, (1) 14-30.
10.1214/19-STS729
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63622
Giuliano AR, Nedjai B, Lorincz AT, Schell MJ, Rahman S, Banwait R, Boulware D, Sirak B et al.(2020). Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. International Journal of Cancer vol. 146, (4) 1018-1030.
10.1002/ijc.32570
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58964
Sasieni P, Cuzick J(2020). Population-level impact of human papillomavirus vaccination. Lancet vol. 395, (10222)
10.1016/S0140-6736(19)33109-5
Li H, Bera K, Gilmore H, Zhang Z, Cuzick J, Thorat MA, Madabhushi A (2020). Computer extracted features of nuclear shape, orientation disorder and texture from H&E Whole slide images are associated with disease-free survival in ductal carcinoma in situ (DCIS). CANCER RESEARCH. vol. 80,
10.1158/1538-7445.SABCS19-P5-06-15
Buus R, Sestak I, Dowsett M, Kronenwett R, Ferree S, Schnabel C, Baehner FL, Cuzick J (2020). Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study. CANCER RESEARCH. Conference: SABCS vol. 80,
10.1158/1538-7445.SABCS19-P3-07-05
Sestak I, Ferree S, Shemesh I, Buckingham W, Cuzick J, Dowsett M (2020). Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer. CANCER RESEARCH. Conference: SABCS vol. 80,
10.1158/1538-7445.SABCS19-P5-06-05
Sestak I, Kronenwett R, Buus R, Cuzick J, Dowsett M (2020). Prognostic value of EndoPredict and Oncotype Recurrence Score according to patient's age. CANCER RESEARCH. Conference: SABCS vol. 80,
10.1158/1538-7445.SABCS19-P5-06-04
Cuzick J, Sestak I, Forbes J, Dowsett M, Cawthorn S, Mansell R, Loibl S, Bonanni B et al. (2020). Ten year results of the international breast cancer intervention study II. CANCER RESEARCH. Conference: SABCS vol. 80,
10.1158/1538-7445.SABCS19-GS4-04
Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CJA et al.(2020). Validation of the OncoMASTR risk score in estrogen receptor–positive/HER2-negative patients: A TransATAC study. Clinical Cancer Research vol. 26, (3) 623-631.
10.1158/1078-0432.CCR-19-0712
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61515
Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J (2020). Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. CANCER RESEARCH. Conference: SABCS vol. 80,
10.1158/1538-7445.SABCS19-GS4-03
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B et al.(2020). Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet vol. 395, (10218) 117-122.
10.1016/S0140-6736(19)32955-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64566
Wang C, Brentnall AR, Mainprize J, Yaffe M, Cuzick J, Harvey JA(2020). External validation of a mammographic texture marker for breast cancer risk in a case-control study. Journal of Medical Imaging vol. 7, (1)
10.1117/1.JMI.7.1.014003
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64579
Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P et al.(2020). Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology
10.1038/s41571-020-0388-9
Dench E, Bond-Smith D, Darcey E, Lee G, Aung YK, Chan A, Cuzick J, Ding ZY et al.(2019). Measurement challenge: Protocol for international case-control comparison of mammographic measures that predict breast cancer risk. BMJ Open vol. 9, (12)
10.1136/bmjopen-2019-031041
Phillips K-A, Liao Y, Milne RL, MacInnis RJ, Collins IM, Buchsbaum R, Weideman PC, Bickerstaffe A et al.(2019). Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. JNCI Cancer Spectr vol. 3, (4)
10.1093/jncics/pkz066
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62618
Noyce AJ, Bandres-Ciga S, Kim J, Heilbron K, Kia D, Hemani G, Xue A, Lawlor DA et al.(2019). The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders vol. 34, (12) 1864-1872.
10.1002/mds.27873
https://qmro.qmul.ac.uk/xmlui/handle/123456789/60502
Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, Moscicki AB, Mahmud SM et al.(2019). Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. JAMA network open vol. 2, (11) e1915781-e1915781.
10.1001/jamanetworkopen.2019.15781
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62625
Sun L, Brentnall A, Patel S, Buist D, Bowles E, Evans DG, Eccles D, Hopper J et al. (2019). SHOULD WE OFFER MULTI-GENE TESTING TO ALL PATIENTS WITH BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. vol. 29, A31-A32.
10.1136/ijgc-2019-ESGO.31
Biganzoli L, Marotti L, Cardoso M-J, Cataliotti L, Curigliano G, Cuzick J, Goldhirsch A, Leidenius M et al.(2019). European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Breast Care vol. 14, (6) 359-365.
10.1159/000503603
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62599
Nedjai B, Hernández-López R, Lorincz A, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, Mendiola-Pastrana I et al.(2019). Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping. Clinical Epigenetics
10.1186/s13148-019-0743-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61917
Nedjai B, Reuter C, Toni H, Austin J, Cadman L, Cuzick J, Lorincz A (2019). Non-invasive methylation test to detect cervical pre-cancer in self-collected vaginal and urine specimens. BRITISH JOURNAL OF CANCER. vol. 121, 12-12.
Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J et al.(2019). A Cost-effectiveness Analysis of Multigene Testing for All Patients with Breast Cancer. JAMA Oncology
10.1001/jamaoncol.2019.3323
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64584
Sun L, Brentnall A, Patel S, Buist SM D, Bowles JA E, Evans R DG, Eccles D, Hopper J et al.(2019). 66 Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis. Regional plenary
10.1136/ijgc-2019-igcs.66
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65196
Kammerer-Jacquet SF, Ahmad A, Møller H, Sandu H, Scardino P, Soosay G, Beltran L, Cuzick J et al.(2019). Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Modern Pathology vol. 32, (9) 1303-1309.
10.1038/s41379-019-0268-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58608
Soliman H, Flake DDII, Magliocco A, Robson M, Schwartzberg L, Sharma P, Brown K, Wehnelt S et al.(2019). Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay. JCO Precision Oncology
10.1200/PO.18.00361
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58986
Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE et al.(2019). Screening performance of abbreviated versions of the UPSIT smell test. J Neurol vol. 266, (8) 1897-1906.
10.1007/s00415-019-09340-x
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57823
Brenner A, Afolabi A, Ahmad SM, Arribas M, Chaudhri R, Coats T, Cuzick J, Gilmore I et al.(2019). Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Trials vol. 20, (1)
10.1186/s13063-019-3561-7
https://qmro.qmul.ac.uk/xmlui/handle/123456789/59722
Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R(2019). Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone vol. 124, 83-88.
10.1016/j.bone.2019.04.016
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57661
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM et al.(2019). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol vol. 30, (7)
10.1093/annonc/mdy537
Cuzick J(2019). Predicting late recurrence in ER-positive breast cancer. Nat Rev Clin Oncol vol. 16, (7) 406-408.
10.1038/s41571-019-0228-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63506
Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG et al.(2019). Prediction of reader estimates of mammographic density using convolutional neural networks. Journal of Medical Imaging vol. 6, (3)
10.1117/1.JMI.6.3.031405
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55611
Sestak I, Zhang Y, Schnabel CA, Cuzick JM, Dowsett M (2019). Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 37,
10.1200/JCO.2019.37.15_suppl.534
Cuzick JM, Stone S, Rajamani S, Moller H, Berney DM, Cohen T, Scardino PT (2019). Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP. JOURNAL OF CLINICAL ONCOLOGY. vol. 37,
10.1200/JCO.2019.37.15_suppl.e16560
Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ et al.(2019). Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. International Journal of Cancer vol. 144, (10) 2587-2595.
10.1002/ijc.31976
https://qmro.qmul.ac.uk/xmlui/handle/123456789/51583
Brentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA(2019). A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. Journal of Breast Imaging vol. 1, (2) 99-106.
10.1093/jbi/wbz006
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58801
Sestak I, Filipits M, Buus R, Rudas M, Knauer M, Kronenwett R, Cuzick J, Gnant MI et al. (2019). Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials. ANNALS OF ONCOLOGY. Conference: ESMO Breast vol. 30,
SESTAK IVANA, CUZICK J(2019). Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment
10.1007/s10549-019-05226-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57640
Berney DM, Beltran L, Sandu H, Soosay G, Møller H, Scardino P, Murphy J, Ahmad A et al.(2019). The percentage of high grade disease in prostate biopsies significantly improves on grade groups in prediction of prostate cancer death. Histopathology
10.1111/his.13888
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61409
Cuzick J, Brentnall A(2019). Commentary on Terry et al., 10-Year Performance of Four Models of Breast Cancer Risk: A Validation Study. Lancet Oncol. 2019;20(4):504-17. Med One vol. 4, (2)
10.20900/mo.20190006
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61141
Boddington C, Bradley R, Braybrooke J, Burrett J, Clarke M, Davies C, Davies L, Dodwell D et al.(2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials. LANCET vol. 393, (10179) 1440-1452.
10.1016/S0140-6736(18)33137-4
Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J et al.(2019). A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet vol. 138, (3) 287-289.
10.1007/s00439-019-01984-z
Dodson A, Sestak I, Bayani J, Dowsett M, Bartlett J, Cuzick J (2019). A newly derived combined clinical treatment score and immunohistochemical-4 prognostic tool. CANCER RESEARCH. Conference: SABCS vol. 79,
10.1158/1538-7445.SABCS18-P2-07-02
Allen N, Allen M, Ahmed K, Gomm J, Nelan R, Nagano A, Chelala C, Gadaleta E et al. (2019). Defining molecular signatures to personalise management of patients with early breast cancer. CANCER RESEARCH. Conference: 2018 San Antonio Breast Cancer Symposium from: 04/12/2019 to: 08/12/2019, vol. 79,
10.1158/1538-7445.SABCS18-P5-18-08
Sestak I, Dowsett M, Cuzick J (2019). Importance of adverse events during endocrine treatment for the prediction of late distant recurrences. CANCER RESEARCH. Conference: SABCS vol. 79,
10.1158/1538-7445.SABCS18-P4-08-02
Sestak I, Martin M, Dubsky P, Rojo F, Cuzick J, Filipits M, Ruiz A, Buus R et al. (2019). Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET plus C) or endocrine therapy alone (ET). CANCER RESEARCH. Conference: SABCS vol. 79,
10.1158/1538-7445.SABCS18-P2-08-04
Phillips K-A, Liao Y, Collins IM, Buchsbaum R, Weideman P, Bickerstaffe A, MacInnis RJ, Cuzick J et al. (2019). Validation of iPrevent using the prospective family study cohort (ProF-SC). CANCER RESEARCH. vol. 79,
10.1158/1538-7445.SABCS18-P4-09-02
Evans DGR, Harkness EF, Brentnall AR, van Veen EM, Astley SM, Byers H, Sampson S, Southworth J et al.(2019). Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Research and Treatment
10.1007/s10549-019-05210-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58802
Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM(2019). Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiology Biomarkers and Prevention vol. 28, (11) 1816-1824.
10.1158/1055-9965.EPI-19-0239
Beltran L, Ahmad AS, Sandu H, Kudahetti S, Soosay G, Møller H, Cuzick J, Berney DM et al.(2018). Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry. Am J Surg Pathol
10.1097/PAS.0000000000001202
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54744
Brentnall AR, Buist DSM, Cuzick J(2018). Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply. JAMA Oncol
10.1001/jamaoncol.2018.5102
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58281
Pegington M, Evans DG, Howell A, Donnelly LS, Wiseman J, Cuzick JM, Harvie MN(2018). Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. Eur J Cancer Prev
10.1097/CEJ.0000000000000493
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54741
Lo L, Collins I, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E et al.(2018). Acceptability and Usability of iPrevent® , a Web-Based Tool for Assessment and Management of Breast Cancer Risk. JMIR Formative Research vol. 2, (2)
10.2196/formative.9935
https://qmro.qmul.ac.uk/xmlui/handle/123456789/48863
Lo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E et al.(2018). The iPrevent online breast cancer risk assessment and risk management tool: Usability and acceptability testing. Journal of Medical Internet Research vol. 20, (11)
10.2196/formative.9935
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54742
Sestak I, Cuzick J (2018). Off-Treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole. JOURNAL OF BONE AND MINERAL RESEARCH. Conference: ASBMR vol. 33, 102-103.
Sestak I, Cuzick J, Blake G, Patel R, Coleman R, Eastell R (2018). Off-treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole. JOURNAL OF BONE AND MINERAL RESEARCH. Conference: ASBMR vol. 33, 46-46.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM et al.(2018). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol vol. 29, (10)
10.1093/annonc/mdx806
van Veen EM, Harkness EF, Brentnall AR, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J et al. (2018). Improving breast cancer risk prediction by combining 18 SNPs, mammographic density and the Tyrer-Cuzick model. EUROPEAN JOURNAL OF HUMAN GENETICS. vol. 26, 681-681.
Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J et al.(2018). Molecular progression to cervical precancer, epigenetic switch or sequential model?. International Journal of Cancer vol. 143, (7) 1720-1730.
10.1002/ijc.31549
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39447
Brenner A, Arribas M, Cuzick J, Jairath V, Stanworth S, Ker K, Shakur-Still H, Roberts I(2018). Outcome measures in clinical trials of treatments for acute severe haemorrhage 11 Medical and Health Sciences 1103 Clinical Sciences. Trials vol. 19, (1)
10.1186/s13063-018-2900-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53529
Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q et al.(2018). Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. Breast Cancer Research vol. 20, (1)
10.1186/s13058-018-1040-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/44789
Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H et al.(2018). Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. eLife vol. 7,
10.7554/eLife.37294
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49643
Atakpa EC, Thorat MA, Cuzick J, Brentnall AR(2018). Mammographic density, endocrine therapy and breast cancer risk: A prognostic and predictive biomarker review. Cochrane Database of Systematic Reviews vol. 2018, (8)
10.1002/14651858.CD013091
https://qmro.qmul.ac.uk/xmlui/handle/123456789/44367
Hackett J, Thorneloe R, Side L, Wolf M, Horne R, Cuzick J, Smith SG(2018). Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews. Breast Cancer Research and Treatment vol. 170, (3) 633-640.
10.1007/s10549-018-4775-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/45463
Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG et al. (2018). Using a convolutional neural network to predict readers' estimates of mammographic density for breast cancer risk assessment. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Conference: 14th International Workshop on Breast Imaging (IWBI 2018) (Atlanta, Georgia, United States) from: 11/07/2018 to: 08/07/2018, vol. 10718,
10.1117/12.2318464
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63614
Lo LL, Milne RL, Liao Y, Cuzick J, Terry MB, Phillips KA(2018). Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ. British Journal of Cancer vol. 119, (1) 36-39.
10.1038/s41416-018-0120-z
https://qmro.qmul.ac.uk/xmlui/handle/123456789/45404
Macis D, Sestak I, Aristarco V, Johansson H, Guerrieri-Gonzaga A, Decensi A, Bonanni B, Cuzick J et al. (2018). Adiponectin, leptin and breast cancer in high risk postmenopausal women: Results from a nested case-control study. CANCER RESEARCH. Conference: AACR vol. 78,
10.1158/1538-7445.AM2018-4216
Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J(2018). Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol vol. 36, (19) 1941-1948.
10.1200/JCO.2017.76.4258
https://qmro.qmul.ac.uk/xmlui/handle/123456789/38903
Cuzick J(2018). The Value of Helicobacter Eradication in Long-term Aspirin Users. J Natl Cancer Inst vol. 110, (7) 690-691.
10.1093/jnci/djx289
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36424
Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S(2018). Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds. Breast Cancer Research vol. 20, (1)
10.1186/s13058-018-0979-x
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39963
Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A et al.(2018). Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations vol. 36, (6) 310.e7-310.e13.
10.1016/j.urolonc.2018.03.011
https://qmro.qmul.ac.uk/xmlui/handle/123456789/37883
Sestak I, Buus R, Cuzick JM, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P et al. (2018). Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 36,
10.1200/JCO.2018.36.15_suppl.553
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64008
Smith SG, Sestak I, Morris MA, Howell A, Forbes JF, Cuzick JM (2018). Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 36,
10.1200/JCO.2018.36.15_suppl.1560
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63736
Sestak I, Zhang Y, Sgroi D, Schnabel CA, Cuzick JM, Dowsett M (2018). Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 36,
10.1200/JCO.2018.36.15_suppl.529
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63704
CUZICK JM(2018). Prognosis vs Treatment Interaction. JNCI: Journal of the National Cancer Institute Cancer Spectrum vol. 2, (1)
10.1093/jncics/pky006
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39067
CUZICK JM(2018). Progress in Preventive Therapy for Cancer – A reminiscence and personal viewpoint. British Journal of Cancer
10.1038/s41416-018-0039-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42286
AHMAD AS, Parameshwaran V, Beltran L, FISHER G, Greenberg D, Soosay G, MOLLER H, Scardino P et al.(2018). Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively. Oncotarget
10.18632/oncotarget.24994
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39505
BRENTNALL AR, CUZICK J, BUIST DSM, BOWLES EA(2018). Long-term accuracy of breast cancer risk assessment combining classical factors and breast density: a cohort study. JAMA Oncology
10.1001/jamaoncol.2018.0174
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36390
Sgroi DC, Sestak I, Cuzick J(2018). Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population (vol 14, pg 1067, 2013). LANCET ONCOLOGY vol. 19, (4) E184-E184.
Kammerer-Jacquet S-F, Ahmad A, Moller H, Scardino P, Beltran L, Cuzick J, Berney D (2018). Ki-67 is an Independent Predictor of Prostate Cancer Death in Routine Sections: Potential Use in Active Surveillance. MODERN PATHOLOGY. vol. 31, 354-354.
Beltran L, North B, Moller H, Scardino P, Cuzick J, Berney D (2018). Prognostic Value of Cancer Extent Assessment in a Conservatively Treated Prostate Biopsy Cohort of 988 Men Using Prostate Cancer Death as Outcome. LABORATORY INVESTIGATION. vol. 98, 327-327.
Mistro A, ADCOCK R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H et al.(2018). Human papilloma virus genotyping for the cross‐sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more. International Journal of Cancer
10.1002/ijc.31326
https://qmro.qmul.ac.uk/xmlui/handle/123456789/44863
SESTAK I, Buus R, CUZICK JM, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D et al.(2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer. JAMA Oncology
10.1001/jamaoncol.2017.5524
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36519
Phillips K-A, Lo L, Bressel M, Collins IM, Emery J, Weideman P, Keogh L, Steel E et al.(2018). Abstract P4-11-02: Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk. Poster Session Abstracts
10.1158/1538-7445.sabcs17-p4-11-02
Astley SM, Harkness EF, Sergeant JC, WARWICK J, Stavrinos P, Warren R, Wilson M, Beetles U et al.(2018). A comparison of five methods of measuring mammographic density: a case-control study. Breast Cancer Research
10.1186/s13058-018-0932-z
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32385
Phillips K-A, Lo L, Bressel M, Collins IM, Emery J, Weideman P, Keogh L, Steel E et al. (2018). Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk. CANCER RESEARCH. vol. 78,
Sestak I, Regan M, Dodson A, Viale G, Thurlimann B, Colleoni M, Cuzick J, Dowsett M (2018). Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy. CANCER RESEARCH. Conference: SABCS vol. 78,
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63433
Sestak I, Smith S, Sleeth M, Howell A, Cuzick J (2018). Participant-reported symptoms as predictors of long-term adherence of endocrine therapy in the International breast cancer intervention studies 2 (IBIS-2). CANCER RESEARCH. Conference: SABCS vol. 78,
Sestak I, Kronenwett R, Denkert C, Cuzick J, Dowsett M (2018). Prognostic performance of EndoPredict in invasive lobular carcinoma. CANCER RESEARCH. Conference: SABCS vol. 78,
Evans DG, BRENTNALL AR, Harvie M, Astley S, Harkness E, Stavrinos P, Donnelly LS, Sampson S et al.(2018). Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. BMC Public Health
10.1186/s12889-018-5090-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31783
van Veen E, BRENTNALL AR, Byers H, Harkness E, Astley S, Sampson S, Howell A, Newman W et al.(2018). Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncology
10.1001/jamaoncol.2017.4881
https://qmro.qmul.ac.uk/xmlui/handle/123456789/37663
Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C et al.(2018). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology vol. 19, (1) 27-39.
10.1016/S1470-2045(17)30777-5
Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M et al.(2018). RAZOR: A phase II open randomized trial of screening plus goserelin and raloxifene versus screening alone in premenopausal women at increased risk of breast cancer. Cancer Epidemiology Biomarkers and Prevention vol. 27, (1) 58-66.
10.1158/1055-9965.EPI-17-0158
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25368
Cuzick J, Brentnall A, Dowsett M(2017). SNPs for breast cancer risk assessment. Oncotarget vol. 8, (59) 99211-99212.
10.18632/oncotarget.22278
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31333
Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, Bartholomew D, Cestero RM et al.(2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet vol. 390, (10108) 2143-2159.
10.1016/S0140-6736(17)31821-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25830
Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J(2017). Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol
10.1093/annonc/mdx713
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32064
Prasher S, Oliver T, Chinegwundoh F, Bhudia R, Cuzick J, Wilks M (2017). Identification of low oxygen tolerating bacteria in prostate secretions of cancer patients: aetiological and therapeutic relevance. LANCET. vol. 390, S71-S71.
10.1016/S0140-6736(17)33006-4
Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S(2017). A novel and fully automated mammographic texture analysis for risk prediction: Results from two case-control studies. Breast Cancer Research vol. 19, (1)
10.1186/s13058-017-0906-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/28809
Smith SG, Foy R, McGowan J, Kobayashi LC, Burn J, Brown K, Side L, Cuzick J(2017). General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey. Fam Cancer vol. 16, (4) 509-516.
10.1007/s10689-017-9986-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22597
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM et al.(2017). Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. Ann Oncol
10.1093/annonc/mdx543
Vasiljevi¿ N, Carter PD, Reuter C, Warman R, Brentnall AR, Carton JR, Cuzick J, Lorincz AT(2017). Role of quantitative p16<sup>INK4A</sup> mRNA assay and digital reading of p16<sup>INK4A</sup> immunostained sections in diagnosis of cervical intraepithelial neoplasia. International Journal of Cancer vol. 141, (4) 829-836.
10.1002/ijc.30783
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23532
Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y(2017). Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after. JNCI: Journal of the National Cancer Institute
10.1093/jnci/djx137
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25526
CUZICK JM(2017). Preventive Therapy for Cancer. Lancet Oncology, The
10.1016/S1470-2045(17)30536-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23111
Stankiewicz E, Xueying M, Mangham DC, Xu L, Yeste-Velasco M, Fisher G, North B, Chaplin T et al.(2017). Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer. Scientific Reports Article 5124,
10.1038/s41598-017-05209-z
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23507
Thorat MA, Cuzick J(2017). Preventing invasive breast cancer using endocrine therapy. Breast
10.1016/j.breast.2017.06.027
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25066
Smith SG, Sestak I, Howell A, Forbes J, Cuzick J(2017). Participant-reported symptoms and their impact on long-term adherence in the International Breast Cancer Intervention Study (IBIS-1). Journal of Clinical Oncology vol. 35, (23)
10.1200/JCO.2016.71.7439
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25333
Cuzick J, Myers O, Lee JH, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM et al.(2017). Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncology vol. 3, (10) 1327-1334.
10.1001/jamaoncol.2017.1040
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25005
Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M et al.(2017). De-escalating and Escalating Treatments for Early Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology vol. 28, (8) 1700-1712.
10.1093/annonc/mdx308
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25828
Petersen LK, Restrepo J, Moreira ED, Iversen O-E, Pitisuttithum P, Van Damme P, Joura EA, Olsson S-E et al.(2017). Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res vol. 3, 105-115.
10.1016/j.pvr.2017.03.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23533
Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee JH, Du R et al.(2017). Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncology vol. 3, (6) 833-837.
10.1001/jamaoncol.2016.3609
Smith SG, Foy R, McGowan JA, Kobayashi LC, DeCensi A, Brown K, Side L, Cuzick J(2017). Prescribing tamoxifen in primary care for the prevention of breast cancer: A national online survey of GPs' attitudes. British Journal of General Practice vol. 67, (659) e414-e427.
10.3399/bjgp17X689377
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19691
Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M et al.(2017). Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. Journal of Clinical Oncology vol. 35, (15) 1641-1649.
10.1200/jco.2016.72.0722
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23112
Lorincz AT, Nathan M, Reuter C, Warman R, THAHA MA, Sheaff M, Vasiljevic N, Ahmad A et al.(2017). Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget vol. 8, (31) 50510-50520.
10.18632/oncotarget.17984
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23519
Lorincz AT, Nathan M, Reuter C, Warman R, Thaha MA, Sheaff M, Vasiljevic N, Ahmad A et al.(2017). Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget vol. 8, (31) 50510-50520.
10.18632/oncotarget.17984
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49428
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA (2017). Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial. TRIALS. Conference: ICTMC/SCT 2017 vol. 18,
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50803
CUZICK JM, Bartlett J, Ikhlaaq A, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimannh B et al.(2017). HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer
10.1016/j.ejca.2017.03.033
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23086
Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel AC, Hajdúch M, Hill C, Walker I et al.(2017). Assessing opportunities for coordinated R&amp;D in early cancer detection and management in Europe. International Journal of Cancer vol. 140, (7) 1700-1701.
10.1002/ijc.30564
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18460
BRENTNALL AR, Sasieni P, Cuzick J(2017). Estimating efficacy in trials with selective crossover. Statistics in Medicine
10.1002/sim.7275
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22470
Cuzick J, Forbes JF(2017). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II):an international, double-blind,randomised placebo-controlled trial (vol 383, pg 1041, 2014). LANCET vol. 389, (10073) 1010-1010.
Cuzick J(2017). Preventing invasive breast cancer using endocrine therapy. BREAST vol. 32, S7-S8.
10.1016/S0960-9776(17)30071-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23175
CUZICK JM, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, Lyons D, Austin J et al.(2017). Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population. Cancer Epidemiology, Biomarkers and Prevention
10.1158/1055-9965.EPI-16-0960
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19556
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C et al. (2017). Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. CANCER RESEARCH. Conference: San Antonio Breast Cancer Symposium vol. 77,
10.1158/1538-7445.SABCS16-S6-05
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32051
Cuzick J, Sestak I, Bianco A, Strobbe L, Bergh J, Hanusch C, Neven P, Dowsett M et al. (2017). Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC. vol. 77, Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
10.1158/1538-7445.SABCS16-P2-09-03
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32244
Smith SG, Sestak I, Forbes J, Howell A, Cuzick JJ (2017). Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1). CANCER RESEARCH. Conference: San Antonio Breast Cancer Symposium vol. 77,
10.1158/1538-7445.SABCS16-S5-03
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25382
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD et al. (2017). Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. CANCER RESEARCH. Conference: San Antonio Breast Cancer Symposium vol. 77,
10.1158/1538-7445.SABCS16-P1-09-06
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22579
Berney D, Ahmad A, Parameshwaran V, Scardino P, Moller H, Cuzick J, Beltran L (2017). Should Reporting of Peri-Neural Invasion and Extra-Capsular Extension Be Mandatory in Prostate Cancer BiopsieS? Correlation with Outcome in 988 Cases Treated Conservatively. MODERN PATHOLOGY. vol. 30, 214A-214A.
Arbyn M, Xu L, Verdoodt F, Cuzick J, Szarewski A, Belinson JL, Wentzensen N, Gage JC et al.(2017). Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis. Ann Intern Med vol. 166, (2) 118-127.
10.7326/M15-2735
https://qmro.qmul.ac.uk/xmlui/handle/123456789/22644
Brentnall AR, Duffy SW, Cuzick J (2017). To the editor. vol. 376, is. 1,
10.1056/NEJMc1614282
Cuzick J(2017). Preventive therapy. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition,
Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y(2017). Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence after Endocrine Therapy of ER+ Breast Cancer. Journal of the National Cancer Institute vol. 110, (2)
10.1093/jnci/djx137
https://qmro.qmul.ac.uk/xmlui/handle/123456789/28597
Nair KP, Harkness EF, Gadde S, Lim YY, Maxwell AJ, Moschidis E, Foden P, Cuzick J et al. (2017). The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. vol. 10134,
10.1117/12.2255619
BRENTNALL AR, Cuzick J(2016). Use of the concordance index for predictors of censored survival data. Statistical Methods in Medical Research
10.1177/0962280216680245
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18788
CUZICK J, BRENTNALL AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I et al.(2016). Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. Journal of Clinical Oncology vol. 35, (7) 743-750.
10.1200/jco.2016.69.8944
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16158
Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM et al.(2016). Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Research vol. 2, 61-69.
10.1016/j.pvr.2016.03.002
Cuzick J, Wheeler C(2016). Need for expanded HPV genotyping for cervical screening. Papillomavirus Res vol. 2, 112-115.
10.1016/j.pvr.2016.05.004
Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N et al. (2016). Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines. Obstet Gynecol. vol. 128, 1248-1257.
10.1097/AOG.0000000000001721
Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A, FH-risk study Group, Newman WG et al.(2016). The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. Journal of Medical Genetics
10.1136/jmedgenet-2016-104125
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16742
Parameshwaran V, North BV, Moller H, Scardino P, Cuzick J, Beltran L, Berney DM (2016). The Significance of Reporting Perineural Invasion in 988 Conservatively Treated Prostate Cancer Patients with Long Term Outcome. JOURNAL OF PATHOLOGY. vol. 240, 21-21.
Timms K, Cuzick J, Neff C, Reid J, Solimeno C, Sangale Z, Pruss D, Gutin A et al. (2016). The molecular landscape of genome instability in prostate cancer (PC). ANNALS OF ONCOLOGY. vol. 27,
10.1093/annonc/mdw363.63
Cuzick J, Ahmad AS, Austin J, Cadman L, Ho L, Terry G, Kleeman M, Ashdown-Barr L et al.(2016). A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4. Journal of Clinical Virology vol. 82, Article C, 145-151.
10.1016/j.jcv.2016.06.015
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14793
Rudolph SE, Lorincz A, Wheeler CM, Gravitt P, Lazcano-Ponce E, Torres-Ibarra L, León-Maldonado L, Ramírez P et al.(2016). Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico. BMC Infect Dis vol. 16, 461-461.
10.1186/s12879-016-1782-x
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17082
McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M, Wheeler CM(2016). Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. Journal of Rural Health
10.1111/jrh.12202
Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A et al.(2016). Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Research and Treatment vol. 158, (3) 591-596.
10.1007/s10549-016-3885-x
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15403
Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A et al.(2016). Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics vol. 138, (2)
10.1542/peds.2015-4387
Šestak I, Cuzick J(2016). Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. Expert Rev Endocrinol Metab vol. 11, (5) 425-432.
10.1080/17446651.2016.1216101
Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J(2016). Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Research and Treatment vol. 159, (1)
10.1007/s10549-016-3868-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15071
Stankiewicz E, Mao X, Mangham DC, Xu L, Fisher G, North B, Moller H, Scardino P et al.(2016). Identification of FBXL4 as a bone metastasis-associated gene in prostate cancer. Scientific Reports vol. 7,
10.1158/1538-7445.AM2016-1614
Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C, Vanden Broeck D, Padalko E, Quint W et al.(2016). Performance of a cartridge based assay for the detection of clinically significant HPV infection – lessons from VALGENT (Validation of HPV Genotyping Tests). Journal of Clinical MicrobiologyJCM.00897-16-JCM.00897-16.
10.1128/JCM.00897-16
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32252
Astley S, Harkness E, Sergeant J, Stavrinos P, Warren R, Wilson M, Brentnall A, Cuzick J et al. (2016). A comparison of four methods of mammographic density measurement in the UK Predicting Risk Of Cancer At Screening (PROCAS) study - on behalf of the PROCAS Study team. EUROPEAN JOURNAL OF CANCER. vol. 61, S6-S6.
Sasieni PD, Duffy SW, Cuzick J (2016). Ovarian cancer screening: UKCTOCS trial. vol. 387, is. 10038,
10.1016/S0140-6736(16)30847-9
Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D(2016). Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer. Clinical Cancer Research vol. 22, (18)
10.1158/1078-0432.CCR-16-0155
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12762
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D et al.(2016). Re: Validation of an RNA Cell Cycle Progression Score for Predicting Death from Prostate Cancer in a Conservatively Managed Needle Biopsy Cohort Editorial Comment. JOURNAL OF UROLOGY vol. 195, (6) 1779-1780.
10.1016/j.juro.2016.03.057
Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J et al.(2016). Validation of a DNA methylation HPV triage classifier in a screening sample. International Journal of Cancer vol. 138, (11) 2745-2751.
10.1002/ijc.30008
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12311
Sestak I, Yeo B, Dodson A, Dowsett M, Cuzick JM (2016). Improved use of clinical variables for prognosis of distant recurrence in patients with ER plus breast cancer treated with 5 years endocrine therapy. JOURNAL OF CLINICAL ONCOLOGY. Conference: ASCO vol. 34,
10.1200/JCO.2016.34.15_suppl.566
Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C et al.(2016). Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute vol. 108, (11)
10.1093/jnci/djw149
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15069
Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW(2016). Impact of screening on breast cancer mortality-response. Cancer Epidemiology Biomarkers and Prevention vol. 25, (5)
10.1158/1055-9965.EPI-16-0170
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S et al.(2016). Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trial. Annals of Oncology vol. 27, (5) 806-812.
10.1093/annonc/mdw055
Evans DGR, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, Watterson D, Fox L et al.(2016). Breast cancer risk feedback to women in the UK NHS breast screening population. British Journal of Cancer vol. 114, (9) 1045-1052.
10.1038/bjc.2016.56
Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P et al.(2016). Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. British Journal of Cancer vol. 114, 1068-1083.
10.1038/bjc.2016.86
Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J et al.(2016). Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. Annals of Oncology vol. 27, (4) 575-590.
10.1093/annonc/mdv590
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11073
Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C et al.(2016). HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex vol. 58, (2) 211-219.
10.21149/spm.v58i2.7790
Bishoff J, Freedland S, Schlomm T, Reid J, Brawer M, Stone S, Cuzick J (2016). THE CCP SCORE PROVIDES SIGNIFICANT PROGNOSTIC INFORMATION IN GLEASON SCORE < 7 PATIENTS. JOURNAL OF UROLOGY. vol. 195, E18-E18.
10.1016/j.juro.2016.02.1892
Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, Rivera B, Ramírez P et al.(2016). Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex vol. 58, (2) 197-210.
10.21149/spm.v58i2.7789
Massat NJ, Sasieni PD, Tataru D, Parmar D, Cuzick J, Duffy SW(2016). Explaining the better prognosis of screening-exposed breast cancers: Influence of tumor characteristics and treatment. Cancer Epidemiology Biomarkers and Prevention vol. 25, (3) 479-487.
10.1158/1055-9965.EPI-15-0804
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11307
Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW(2016). Impact of screening on breast cancer mortality: The UK program 20 years on. Cancer Epidemiology Biomarkers and Prevention vol. 25, (3) 455-462.
10.1158/1055-9965.EPI-15-0803
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10511
Smith S, Meisel SF, Home R, Cuzick J, Wardle J (2016). POISON OR PREVENTION? PATIENT AND CLINICIAN ATTITUDES TOWARDS BREAST CANCER CHEMOPREVENTION. ANNALS OF BEHAVIORAL MEDICINE. vol. 50, S329-S329.
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W et al.(2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet vol. 387, (10021) 866-873.
10.1016/S0140-6736(15)01129-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12300
Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G et al. (2016). Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS). CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-S6-03
Dowsett M, Sestak I, Buus R, Kronenwett R, Denkert C, Krappmann K, Scheer M, Petry C et al. (2016). EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2-breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS). CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-S3-01
Smith SG, Sestak I, Forster A, Partridge A, Side L, Horne R, Wardle J, Cuzick J (2016). Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-PD1-08
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thurlimann BJK, Seynaeve C et al. (2016). HER2 status as predictive marker for Al vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-S4-06
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA (2016). Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-P2-08-12
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA (2016). Integration of tumor size and grade with the breast cancer index (BCl) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. CANCER RESEARCH. vol. 76,
Evans DG, Astley SM, Brentnall A, Howell A, Cuzick J (2016). Mammographic density and SNPs add to Tyrer-Cuzick and Gail model breast cancer risk in a UK screening cohort. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-PD1-07
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, II FDD et al. (2016). Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. CANCER RESEARCH. vol. 76,
Zhang Y, Sestak I, Schroeder BE, Dowsett M, Cuzick J, Schnabel CA, Sgroi DC (2016). Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study. CANCER RESEARCH. vol. 76,
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF et al. (2016). Prognostic role and impact of multi -clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. CANCER RESEARCH. vol. 76,
Thorat MA, Jones LJ, Levey PM, Elia G, Evagora CA, Bundred NJ, Fentiman IS, Forbes JF et al. (2016). Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. CANCER RESEARCH. vol. 76,
10.1158/1538-7445.SABCS15-P3-07-01
Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM et al.(2016). Cancer Prevention: Obstacles, Challenges, and the Road Ahead. Journal of the National Cancer Institute vol. 108, (2)
10.1093/jnci/djv309
Cuzick J, Wickerham L, Powles T(2016). Differing perspectives on breast cancer chemoprevention. JAMA Oncology vol. 2, (2) 276-277.
10.1001/jamaoncol.2015.4406
Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J et al.(2016). HPV-FASTER: Broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology vol. 13, (2) 119-132.
10.1038/nrclinonc.2015.146
Berney D, Fisher G, North B, Moller H, Scardino P, Cuzick J, Beltran L (2016). Validation of Reporting Percentage High Grade Prostate Cancer in 988 Conservatively Treated Patients with Long Term Outcome. MODERN PATHOLOGY. vol. 29, 217A-217A.
Collins IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P et al.(2016). iPrevent<sup>®</sup>: a tailored, web-based, decision support tool for breast cancer risk assessment and management. Breast Cancer Research and Treatment vol. 156, (1) 171-182.
10.1007/s10549-016-3726-y
Vélez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J(2016). Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open vol. 6, (1)
10.1136/bmjopen-2015-009584
Scardino PT, Cuzick JM, Stone S, Evans B, Jorgensen MR, Eastham JA, Keane TE, Davis JW et al. (2016). Application of active surveillance threshold to series of samples submitted for commercial testing. JOURNAL OF CLINICAL ONCOLOGY. vol. 34,
10.1200/jco.2016.34.2_suppl.84
Ahmad AS, Vasiljevi¿ N, Carter P, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT(2016). A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors. Oncotarget vol. 7, (44) 71833-71840.
10.18632/oncotarget.12377
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16201
Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE et al.(2016). Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology: Results from a state-wide surveillance program. Cancer Epidemiology Biomarkers and Prevention vol. 25, (1) 36-42.
10.1158/1055-9965.EPI-15-0669
Phillips KA, Steel EJ, Collins I, Emery J, Pirotta M, Mann GB, Butow P, Hopper JL et al.(2016). Transitioning to routine breast cancer risk assessment and management in primary care: What can we learn from cardiovascular disease?. Australian Journal of Primary Health vol. 22, (3) 255-261.
10.1071/PY14156
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6926
Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A(2015). PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. Clinical Oncology vol. 28, (5) 317-326.
10.1016/j.clon.2015.11.008
Brentnall AR, Harkness EF, Astley SM, Donnelly LS, Stavrinos P, Sampson S, Fox L, Sergeant JC et al.(2015). Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Research
10.1186/s13058-015-0653-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10858
Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C et al.(2015). Performance of the Xpert HPV assay in women attending for cervical screening. Papillomavirus Research vol. 1, 32-37.
10.1016/j.pvr.2015.05.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12232
Cuzick J(2015). Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. Ann Oncol vol. 26, (12) 2363-2366.
10.1093/annonc/mdv392
DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J(2015). Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. ecancermedicalscience vol. 9,
10.3332/ecancer.2015.595
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11074
Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J(2015). Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Journal of Clinical Oncology vol. 34, (2) 139-143.
10.1200/JCO.2015.63.4972
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13796
Cuzick J, Sestak I, Thorat MA(2015). Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast vol. 24, S51-S55.
10.1016/j.breast.2015.07.013
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12172
Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A et al.(2015). Inefficiencies and high-value improvements in U.S. cervical cancer screening practice: A cost-effectiveness analysis. Annals of Internal Medicine vol. 163, (8) 589-597.
10.7326/M15-0420
Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J et al.(2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. The Lancet vol. 386, (10001) 1353-1361.
10.1016/S0140-6736(15)60908-4
Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, Gettins L, Godwin J et al.(2015). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet vol. 386, (10001) 1341-1352.
10.1016/S0140-6736(15)61074-1
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O et al.(2015). Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. Cancer Prev Res (Phila) vol. 8, (10) 888-894.
10.1158/1940-6207.CAPR-15-0048
Paleari L, Puntoni M, Clavarezza M, Corradengo D, Campazzi E, Caviglia S, Provinciali N, Cuzick J et al.(2015). PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. ANNALS OF ONCOLOGY vol. 26, 36-36.
Reid JL, Wright TC, Stoler MH, Cuzick J, Castle PE, Dockter J, Getman D, Giachetti C(2015). Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. Am J Clin Pathol vol. 144, (3) 473-483.
10.1309/AJCPHVD7MIP3FYVV
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P et al.(2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol vol. 26, (8) 1685-1691.
10.1093/annonc/mdv215
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7588
Haviland JS, Bliss JM, Bentzen SM, Cuzick J(2015). In Regard to Vaidya et al. Int J Radiat Oncol Biol Phys vol. 92, (5) 954-955.
10.1016/j.ijrobp.2015.05.026
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D et al.(2015). Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer vol. 113, (3) 382-389.
10.1038/bjc.2015.223
Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y et al.(2015). A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women. OBSTETRICAL & GYNECOLOGICAL SURVEY vol. 70, (7) 446-448.
10.1097/OGX.0000000000000206
Trinh T, Christensen SE, Brand JS, Cuzick J, Czene K, Sjölander A, Bälter K, Hall P(2015). Background risk of breast cancer influences the association between alcohol consumption and mammographic density. Br J Cancer vol. 113, (1) 159-165.
10.1038/bjc.2015.185
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A et al.(2015). Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clin Cancer Res vol. 21, (12) 2763-2770.
10.1158/1078-0432.CCR-14-2842
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7862
Cuzick J, Myers O, Hunt WC, Saslow D, Castle PE, Kinney W, Waxman A, Robertson M et al.(2015). Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management. Int J Cancer vol. 136, (12) 2854-2863.
10.1002/ijc.29337
Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D et al.(2015). Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Res Treat vol. 151, (2) 309-318.
10.1007/s10549-015-3397-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7627
Zhang Y, Sestak I, Cuzick JM, Dowsett M, Schnabel CA, Sgroi D (2015). Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.526
Cuzick JM, Stone S, Fisher G, North B, Berney DM, Beltran L, Greenberg D, Moller H et al. (2015). Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.15_suppl.e16040
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF (2015). 16 year long-term follow-up of the IBIS-I breast cancer prevention trial. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-S3-07
Sestak I, Zhang Y, Schroeder BE, Goss PE, Dowsett M, Sgroi DC, Schnabel CA, Cuzick J (2015). Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER plus breast cancer. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-P4-11-19
Guerrieri-Gonzaga A, Macis D, Gandini S, Aristarco V, Johansson H, Bollani G, Roth T, Sandri M-T et al. (2015). Low serum adiponectin level is an independent risk factor of DCIS in postmenopausal women at increased risk of breast cancer. CANCER RESEARCH. vol. 75,
Hiscox S, Smith C, Nicholson RI, Gee J, Harris A, Bliss J, Kalaizak E, Sestak I et al. (2015). Nuclear beta-catenin negativity predicts for late relapse in ER plus , tamoxifen-treated breast cancer. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-P3-06-01
Howell A, Astley S, Harkness E, Wiseman J, Fox J, Stavrinos P, Wilson M, Lim Y et al. (2015). Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-P5-12-01
Sestak I, Howell A, Forbes JF, Neven P, Cuzick J (2015). Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.SABCS14-PD4-1
Møller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, Overvad K, Tjønneland A(2015). Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer vol. 136, (8) 1940-1947.
10.1002/ijc.29238
Cuzick J(2015). Radiotherapy for breast cancer, the TARGIT-A trial (vol 383, pg 1716, 2014). LANCET vol. 385, (9976) 1396-1396.
Trinh T, Eriksson M, Darabi H, Bonn SE, Brand JS, Cuzick J, Czene K, Sjölander A et al.(2015). Background risk of breast cancer and the association between physical activity and mammographic density. Breast Cancer Res vol. 17,
10.1186/s13058-015-0565-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7594
Cuzick J, Stone S, Reid J, Fisher G, Moller H, Brawer M, Scardino P, Shore N (2015). PATIENT AUA RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE. JOURNAL OF UROLOGY. vol. 193, E3-E3.
10.1016/j.juro.2015.02.171
Cuzick J, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D et al. (2015). VALIDATION OF AN ACTIVE SURVEILLANCE THRESHOLD FOR THE CCP SCORE IN CONSERVATIVELY MANAGED MEN WITH LOCALIZED PROSTATE CANCER. JOURNAL OF UROLOGY. vol. 193, E4-E4.
10.1016/j.juro.2015.02.173
Brentnall AR, Cuzick J(2015). Atypical Hyperplasia of the Breast. NEW ENGLAND JOURNAL OF MEDICINE vol. 372, (13) 1269-1270.
10.1056/NEJMc1501046
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7565
Brentnall AR, Cuzick J(2015). Atypical hyperplasia of the breast. The New England journal of medicine vol. 372, (13) 1269-1270.
10.1056/NEJMc1501046#SA1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11984
Louvanto K, Franco EL, Ramanakumar AV, Vasiljevi¿ N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F et al.(2015). Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer vol. 136, (6) E638-E645.
10.1002/ijc.29196
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S et al.(2015). Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol vol. 33, (8) 916-922.
10.1200/JCO.2014.55.6894
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16982
Kylstra JW, Kalnoski M, Quay S, Chen S, Vo T, Cuzick J(2015). Nipple aspirate fluid (NAF) cytology in the IBIS-model prediction of breast cancer (BCA) risk. BREAST vol. 24, S68-S69.
10.1016/S0960-9776(15)70170-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7591
Cuzick J, Thorat M (2015). Preventing invasive breast cancer in women at high risk based on benign/in situ pathology. BREAST. vol. 24, S11-S11.
10.1016/S0960-9776(15)70024-X
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7628
Stone S, Cuzick JM, Fisher G, Yang ZH, North B, Berney DM, Beltran L, Greenberg D et al. (2015). Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
10.1200/jco.2015.33.7_suppl.54
Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y et al.(2015). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med vol. 372, (8) 711-723.
10.1056/NEJMoa1405044
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6927
Brentnall AR, Cuzick J, Field J, Duffy SW(2015). A concordance index for matched case-control studies with applications in cancer risk. Stat Med vol. 34, (3) 396-405.
10.1002/sim.6335
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12301
Castle PE, Cuzick J, Stoler MH, Wright TC, Reid JL, Dockter J, Giachetti C, Getman D(2015). Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. Am J Clin Pathol vol. 143, (2) 160-167.
10.1309/AJCPLCD8TTOMLJTB
Beltran L, North B, Fisher G, Moller H, Scardino P, Cuzick J, Berney D (2015). Long Term Outcome in a Biopsy Cohort of 988 Conservatively Treated Prostate Cancers. Evidence for Revised Gleason Grading and Use of the Worst Scoring Core. LABORATORY INVESTIGATION. vol. 95, 207A-208A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7125
Sestak I, Cuzick J(2015). Update on breast cancer risk prediction and prevention. Curr Opin Obstet Gynecol vol. 27, (1) 92-97.
10.1097/GCO.0000000000000153
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6786
Almonte M, Ferreccio C, Luciani S, Gonzales M, Delgado JM, Santos C, Alvarez M, Cuzick J et al.(2015). Visual Inspection after Acetic Acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru. PLoS ONE vol. 10, (1)
10.1371/journal.pone.0115355
Sestak I, Cuzick J(2015). Markers for the identification of late breast cancer recurrence. Breast Cancer Res vol. 17,
10.1186/s13058-015-0516-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7755
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ et al.(2015). Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol vol. 26, (1) 47-57.
10.1093/annonc/mdu225
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10452
Cuzick J(2015). Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines vol. 14, (8) 1047-1049.
10.1586/14760584.2015.1051470
Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, Lorincz AT(2015). HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and EPB41L3 methylation classifier. Cancer Biomarkers vol. 15, (5) 669-675.
10.3233/CBM-150507
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9289
Cuzick J, Thorat MA(2015). PSA testing for prostate cancer screening - Authors' reply. The Lancet Oncology vol. 16, (1)
10.1016/S1470-2045(14)71189-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10451
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, IBIS-I Investigators(2015). Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol vol. 16, (1) 67-75.
10.1016/S1470-2045(14)71171-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6566
Stoler MH, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM, Kinney W, Waxman A et al.(2015). The interpretive variability of cervical biopsies and its relationship to HPV status. American Journal of Surgical Pathology vol. 39, (6) 729-736.
10.1097/PAS.0000000000000381
Sestak I, Singh S, Cuzick J(2014). Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, doubleblind, randomised, placebo-controlled trial (vol 15, pg 1464, 2014). LANCET ONCOLOGY vol. 15, (13) E587-E587.
Yang Z, Cuzick J, Hunt WC, Wheeler CM(2014). Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol vol. 180, (11) 1066-1075.
10.1093/aje/kwu267
Cuzick J(2014). Endpoints for the evaluation of breast cancer treatments. J Natl Cancer Inst vol. 106, (12)
10.1093/jnci/dju323
Thorat MA, Cuzick J(2014). Reply to the Letter to the Editor "The harms of low-dose aspirin prophylaxis are overstated" by P. Elwood and G. Morgan. Annals of Oncology
10.1093/annonc/mdu546
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10493
Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M et al.(2014). Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology vol. 15, (13) 1460-1468.
10.1016/S1470-2045(14)71035-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14962
Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC et al.(2014). The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathol vol. 122, (11) 842-850.
10.1002/cncy.21463
Warwick J, Birke H, Stone J, Warren RML, Pinney E, Brentnall AR, Duffy SW, Howell A et al.(2014). Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res vol. 16, (5)
10.1186/s13058-014-0451-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10782
Collins IM, Steel E, Mann GB, Emery JD, Bickerstaffe A, Trainer A, Butow P, Pirotta M et al.(2014). Assessing and managing breast cancer risk: clinicians' current practice and future needs. Breast vol. 23, (5) 644-650.
10.1016/j.breast.2014.06.014
Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR et al.(2014). Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev vol. 23, (10) 1997-2008.
10.1158/1055-9965.EPI-14-0410
Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, Astley S, Wilson M et al.(2014). Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res (Phila) vol. 7, (10) 993-1001.
10.1158/1940-6207.CAPR-14-0037
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG et al.(2014). Prevention and early detection of prostate cancer. Lancet Oncol vol. 15, (11) e484-e492.
10.1016/S1470-2045(14)70211-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10492
Brentnall AR, Vasiljevi¿ N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, Cuzick J, Lorincz AT(2014). A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer vol. 135, (6) 1425-1432.
10.1002/ijc.28790
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11422
Vasiljevi¿ N, Ahmad AS, Thorat MA, Fisher G, Berney DM, Møller H, Foster CS, Cuzick J et al.(2014). DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer vol. 14,
10.1186/1471-2407-14-655
https://qmro.qmul.ac.uk/xmlui/handle/123456789/8527
Cuzick J(2014). Editorial comment. J Urol vol. 192, (2)
10.1016/j.juro.2014.02.2584
Cuzick J(2014). Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy EDITORIAL COMMENT. JOURNAL OF UROLOGY vol. 192, (2) 414-414.
10.1016/j.juro.2014.02.2584
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE, New Mexico HPV Pap Registry Steering Committee(2014). The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States. Int J Cancer vol. 135, (3) 624-634.
10.1002/ijc.28605
Juraskova I, Butow P, Bonner C, Bell ML, Smith AB, Seccombe M, Boyle F, Reaby L et al.(2014). Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial. Br J Cancer vol. 111, (1) 1-7.
10.1038/bjc.2014.144
Cuzick J(2014). Progress in breast cancer prevention. EUROPEAN JOURNAL OF CANCER vol. 50, S7-S7.
10.1016/S0959-8049(14)50026-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7579
Sestak I, Zhang Y, Schnabel CA, Schroeder B, Ander ME, Goss PE, Cuzick JM, Dowsett M et al. (2014). Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR plus early-stage breast cancer: A TransATAC study. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.532
Forbes JF, Dowsett M, Bradley R, Ingle JN, Aihara T, Bliss JM, Boccardo FM, Coates AS et al. (2014). Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam). JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.529
Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N et al. (2014). Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.1519
Cuzick JM, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D et al. (2014). Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. JOURNAL OF CLINICAL ONCOLOGY. vol. 32,
10.1200/jco.2014.32.15_suppl.5059
Cuzick J(2014). Radiotherapy for breast cancer, the TARGIT-A trial. Lancet vol. 383, (9930)
10.1016/S0140-6736(14)60825-4
Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, Benard VB, Wheeler CM et al.(2014). A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev vol. 23, (5) 765-773.
10.1158/1055-9965.EPI-13-0973
Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L et al.(2014). Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol vol. 60, (1) 44-49.
10.1016/j.jcv.2014.02.002
Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, Juraskova I, Stavrinos P et al.(2014). Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer vol. 110, (7) 1681-1687.
10.1038/bjc.2014.109
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M et al. (2014). EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II). OSTEOPOROSIS INTERNATIONAL. vol. 25, S281-S281.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7032
Cuzick J, Stone S, Yang ZH, Reid J, Fisher G, Berney D, Beltran L, Moller H et al. (2014). VALIDATION OF A 46-GENE CELL CYCLE PROGRESSION (CCP) RNA SIGNATURE FOR PREDICTING PROSTATE CANCER DEATH IN A CONSERVATIVELY MANAGED WATCHFUL WAITING NEEDLE BIOPSY COHORT. JOURNAL OF UROLOGY. vol. 191, E936-E936.
10.1016/j.juro.2014.02.2520
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N et al.(2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet vol. 383, (9922) 1041-1048.
10.1016/S0140-6736(13)62292-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12403
Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G et al.(2014). Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer vol. 110, (6) 1655-1662.
10.1038/bjc.2014.13
Vasiljevi¿ N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A(2014). A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol vol. 59, (3) 161-166.
10.1016/j.jcv.2013.12.014
Evans G, Stavrinos P, Dawe S, Harvie M, Wilson M, Maxwell A, Brentnall A, Cuzick J et al. (2014). Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: First prospective results from PROCAS. EUROPEAN JOURNAL OF CANCER. vol. 50, S3-S4.
10.1016/S0959-8049(14)70116-9
Kinney W, Hunt WC, Dinkelspiel H, Robertson M, Cuzick J, Wheeler CM, New Mexico HPV Pap Registry Steering Committee(2014). Cervical excisional treatment of young women: a population-based study. Gynecol Oncol vol. 132, (3) 628-635.
10.1016/j.ygyno.2013.12.037
Vasiljevi¿ N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT(2014). Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol vol. 132, (3) 709-714.
10.1016/j.ygyno.2014.02.001
Ejegod DM, Serrano I, Cuschieri KS, Nussbaumer WA, Vaughan LM, Ahmad AS, Cuzick J, Bonde J (2014). Inter and intra laboratory reproducibility of BD Onclarity HPV assay in ThinPrep primarily screening samples. APMIS. vol. 122, 30-30.
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Cuzick J (2014). Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2-breast cancer. EUROPEAN JOURNAL OF CANCER. vol. 50, S105-S106.
Cuzick J (2014). The prevention of breast cancer. EUROPEAN JOURNAL OF CANCER. vol. 50, S34-S35.
10.1016/S0959-8049(14)70069-3
Brentnall AR, Evans DG, Cuzick J(2014). Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. Br J Cancer vol. 110, (3) 827-828.
10.1038/bjc.2013.747
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11420
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N et al.(2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet vol. 383, (9916) 524-532.
10.1016/s0140-6736(13)62218-7
Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF et al. (2014). Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial. JOURNAL OF BONE AND MINERAL RESEARCH. vol. 29, S110-S110.
Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA et al.(2014). Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res vol. 20, (2) 344-357.
10.1158/1078-0432.CCR-13-1504
Castañón A, Landy R, Cuzick J, Sasieni P(2014). Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med vol. 11, (1)
10.1371/journal.pmed.1001585
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9992
Vasiljevi¿ N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT(2014). DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med vol. 8, (9) 1143-1150.
10.2217/bmm.14.41
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9728
McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G et al.(2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. The Lancet vol. 383, (9935) 2127-2135.
10.1016/S0140-6736(14)60488-8
Cuzick J, Thorat MA(2014). Preface.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14932
Cuzick J(2014). Prognostic value of a cell cycle progression score for men with prostate cancer. Recent Results Cancer Res vol. 202, 133-140.
10.1007/978-3-642-45195-9_16
Thorat M, Cuzick J(2014). Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. European Journal of Epidemiology vol. 30, (1) 5-18.
10.1007/s10654-014-9971-7
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10494
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M et al.(2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine vol. 31, H1-H31.
10.1016/j.vaccine.2013.10.003
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M et al.(2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine vol. 31 Suppl 6, G1-31.
10.1016/j.vaccine.2013.10.002
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M et al.(2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine vol. 31 Suppl 5, F1-31.
10.1016/j.vaccine.2013.10.001
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N et al. (2013). Breast cancer prevention using anastrozole in postmenopausal women at high risk. CANCER RESEARCH. vol. 73,
10.1158/0008-5472.SABCS13S3-01
Sestak I, Cuzick J, Dowsett M, Filipits M, Dubsky P, Cowens W, Ferree S, Schaper C et al.(2013). Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. CANCER RESEARCH vol. 73,
10.1158/0008-5472.SABCS13-S6-04
Cuzick J(2013). Duration of Aromatase Inhibitor Treatment in Breast Cancer: The Role of the 'Carryover Effect'. ONCOLOGY-NEW YORK vol. 27, (12) 1224-1225.
Thorat MA, Cuzick J(2013). Role of aspirin in cancer prevention. Curr Oncol Rep vol. 15, (6) 533-540.
10.1007/s11912-013-0351-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10490
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M et al.(2013). Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine vol. 31, (SUPPL.8) 11-131.
10.1016/j.vaccine.2013.07.026
Bosch FX, Broker TR, Forman D, Moscicki A-B, Gillison ML, Doorbar J, Stern PL, Stanley M et al.(2013). Comprehensive control of human papillomavirus infections and related diseases. Vaccine vol. 31 Suppl 8, I1-31.
10.1016/j.vaccine.2013.07.026
Cuzick J, Yang Z(2013). A frailty model for interaction between multiple events. JOURNAL OF MULTIVARIATE ANALYSIS vol. 122, 133-147.
10.1016/j.jmva.2013.07.012
Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J(2013). Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst vol. 105, (19) 1504-1511.
10.1093/jnci/djt244
https://qmro.qmul.ac.uk/xmlui/handle/123456789/8003
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A et al.(2013). Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol vol. 14, (11) 1067-1076.
10.1016/S1470-2045(13)70387-5
Collins IM, Keogh LA, Steel E, Emery J, Pirotta M, Mann B, Butow P, Trainer A et al. (2013). Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
10.1200/jco.2013.31.26_suppl.17
Cuzick J (2013). Should all men receive PSA screening?. EUROPEAN JOURNAL OF CANCER. vol. 49, S20-S20.
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A et al.(2013). Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol vol. 31, (23) 2942-2962.
10.1200/JCO.2013.49.3122
Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J et al.(2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol vol. 31, (22) 2783-2790.
10.1200/JCO.2012.46.1558
Lorincz AT, Brentnall AR, Vasiljevi¿ N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A et al.(2013). HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer vol. 133, (3) 637-644.
10.1002/ijc.28050
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11423
Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J(2013). Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat vol. 140, (2) 253-262.
10.1007/s10549-013-2628-5
Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S et al.(2013). Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer vol. 108, (12) 2582-2589.
10.1038/bjc.2013.248
Mesher D, Szarewski A, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Young M et al.(2013). Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. Eur J Cancer vol. 49, (9) 2179-2186.
10.1016/j.ejca.2013.01.018
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF et al.(2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet vol. 381, (9880) 1827-1834.
10.1016/S0140-6736(13)60140-3
Pugliano L, Zardavas D, Paesmans M, Sestak I, Gelber RD, Cuzick JM, Dowsett M, Awada A et al. (2013). A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER plus BC?. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Phillips K-A, Keogh LA, Steel E, Collins IM, Emery J, Pirotta M, Mann B, Butow P et al. (2013). Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Collins IM, Keogh LA, Steel E, Mann B, Emery J, Pirotta M, Moreton J, Butow P et al. (2013). Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO et al. (2013). Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR plus early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Brawer MK, Cuzick JM, Cooperberg MR, Swanson GP, Freedland SJ, Reid JE, Fisher G, Lanchbury JS et al. (2013). Prolaris: A novel genetic test for prostate cancer prognosis. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S et al.(2013). Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer vol. 108, (4) 908-913.
10.1038/bjc.2013.22
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32406
Vasiljevi¿ N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Møller H, Yu Y et al.(2013). Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis vol. 16, (1) 35-40.
10.1038/pcan.2012.47
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10470
Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, Athena HPV Study Group(2013). Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol vol. 208, (3) 184.e1-184.e11.
10.1016/j.ajog.2012.11.020
Brawer MK, Cooperberg MR, Freedland SJ, Swanson GP, Stone S, Reid JE, Gutin A, Carroll P et al. (2013). Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
10.1200/jco.2013.31.6_suppl.67
Cuzick J, Thomas Cox J, Zhang G, Einstein MH, Stoler M, Trupin S, Behrens CM(2013). Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int J Cancer vol. 132, (4) 959-966.
10.1002/ijc.27723
Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, Berney DM, Transatlantic Prostate Group(2013). Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer vol. 108, (2) 271-277.
10.1038/bjc.2012.598
Stoler MH, Wright TC, Cuzick J, Dockter J, Reid JL, Getman D, Giachetti C(2013). APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol vol. 208, (2) 144.e1-144.e8.
10.1016/j.ajog.2012.12.003
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M et al. (2013). Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II). JOURNAL OF BONE AND MINERAL RESEARCH. vol. 28,
Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S et al.(2013). Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol vol. 14, (2) 168-176.
10.1016/S1470-2045(12)70529-6
Ahmad I, Singh LB, Yang ZH, Kalna G, Fleming J, Fisher G, Cooper C, Cuzick J et al.(2013). Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br J Cancer vol. 108, (1) 149-154.
10.1038/bjc.2012.510
Palva T, Ranta H, Koivisto A-M, Pylkkänen L, Cuzick J, Holli K(2013). A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - a substudy for IBIS I Breast Cancer Prevention Trial. Eur J Cancer vol. 49, (1) 45-51.
10.1016/j.ejca.2012.06.015
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA et al.(2013). A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer vol. 132, (1) 198-207.
10.1002/ijc.27608
von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S et al.(2013). European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication. ENDOSCOPY vol. 45, (1) 51-59.
10.1055/s-0032-1325997
Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S et al.(2013). The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer vol. 132, (1) 101-108.
10.1002/ijc.27636
Sainsbury R, Loddo M, Proctor I, Stoeber K, Williams G, Thorat M, Cuzick J (2012). Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of 'intermediate grade' disease and gives clinically meanignful information. CANCER RESEARCH. vol. 72,
10.1158/0008-5472.SABCS12-PD04-08
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M(2012). Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study. CANCER RESEARCH vol. 72,
10.1158/0008-5472.SABCS12-S1-9
Sgroi DC, Sestak I, Zhang Y, Erlander MG, Schnabel CA, Goss PE, Cuzick J, Dowsett M(2012). Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study. CANCER RESEARCH vol. 72,
10.1158/0008-5472.SABCS12-P2-10-15
Motion J, Ashcroft L, Dowsett M, Cuzick J, Hickman J, Evans G, Eccles D, Eeles R et al.(2012). The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer. CANCER RESEARCH vol. 72,
10.1158/0008-5472.SABCS12-P1-09-05
Sestak I, Cuzick J(2012). Preventive therapy for breast cancer. Curr Oncol Rep vol. 14, (6) 568-573.
10.1007/s11912-012-0273-5
Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, J L M Meijer C, Sankaranarayanan R et al.(2012). New technologies and procedures for cervical cancer screening. Vaccine vol. 30 Suppl 5, F107-F116.
10.1016/j.vaccine.2012.05.088
Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M(2012). Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine vol. 30 Suppl 5, F100-F106.
10.1016/j.vaccine.2012.04.105
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M(2012). CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients (vol 104, pg 452, 2012). JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 104, (22) 1772-1772.
10.1093/jnci/djs443
Cuzick J (2012). HPV ELIMINATION OF CERVICAL CANCER: THE NOVEL OPTIONS IN VACCINATION AND SCREENING. ANNALS OF ONCOLOGY. vol. 23, 53-53.
Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M (2012). PREDICTION OF LATE BREAST CANCER RECURRENCE BY THE ROR (PAM50) SCORE IN POSTMENOPAUSAL WOMEN IN THE TRANSATAC COHORT. ANNALS OF ONCOLOGY. vol. 23, 75-76.
Cuzick J(2012). Breast density predicts endocrine treatment outcome in the adjuvant setting. Breast Cancer Res vol. 14, (4)
10.1186/bcr3235
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5180
Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Møller H, Cooper CS, Cuzick J, Berney DM et al.(2012). Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch vol. 461, (2) 103-107.
10.1007/s00428-012-1259-2
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M(2012). Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response. JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 104, (16) 1267-1268.
10.1093/jnci/djs302
Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J(2012). Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer vol. 107, (2) 230-233.
10.1038/bjc.2012.278
https://qmro.qmul.ac.uk/xmlui/handle/123456789/8025
Evans DGR, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B et al.(2012). Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila) vol. 5, (7) 943-951.
10.1158/1940-6207.CAPR-11-0458
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J(2012). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat vol. 134, (2) 727-734.
10.1007/s10549-012-2085-6
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C(2012). Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol vol. 23, (6) 1403-1415.
10.1093/annonc/mds113
Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S et al.(2012). Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol vol. 50, (6) 1867-1873.
10.1128/JCM.00181-12
Stankiewicz E, Ng M, Cuzick J, Mesher D, Watkin N, Lam W, Corbishley C, Berney DM(2012). The prognostic value of Ki-67 expression in penile squamous cell carcinoma. J Clin Pathol vol. 65, (6) 534-537.
10.1136/jclinpath-2011-200638
Howell A, Cuzick J(2012). Oestrogen and breast cancer: results from the WHI trial. Lancet Oncol vol. 13, (5) 437-438.
10.1016/S1470-2045(12)70110-9
Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M et al.(2012). [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Epidemiol Prev vol. 36, (3-4 Suppl 1) e1-72.
Ronco G, Meijer CJL, Cuzick J, Giorgi-Rossi P, Peto J, Segnan N, Dillner J(2012). Screening for cervical cancer. Ann Intern Med vol. 156, (8) 604-605.
10.7326/0003-4819-156-8-201204170-00011
Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M et al.(2012). Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res vol. 14, (2)
10.1186/bcr3161
Allawi Z, Cuzick J, Baum M, ATAC/LATTE investigators(2012). Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?. Ann Oncol vol. 23, (4) 866-869.
10.1093/annonc/mdr316
Singh S, Cuzick J, Mesher D, Richmond B, Howell A(2012). Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat vol. 132, (2) 625-629.
10.1007/s10549-011-1911-6
Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B et al.(2012). Prevention of breast cancer in the context of a national breast screening programme. J Intern Med vol. 271, (4) 321-330.
10.1111/j.1365-2796.2012.02525.x
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I et al.(2012). CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst vol. 104, (6) 452-460.
10.1093/jnci/djs126
Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I et al.(2012). ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res vol. 14, (2)
10.1186/bcr3145
https://qmro.qmul.ac.uk/xmlui/handle/123456789/4725
Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J et al.(2012). Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer vol. 106, (6) 1095-1099.
10.1038/bjc.2012.39
Cuzick J (2012). The Role of HPV Testing in Cervical Screening. JOURNAL OF PATHOLOGY. vol. 226, S2-S2.
Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, Buyse M, Cameron D et al.(2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. LANCET vol. 379, (9814) 432-444.
10.1016/S0140-6736(11)61625-5
Jeetle SS, Yang ZH, Stankiewicz E, Fisher G, Cooper C, Foster CS, Moller H, Scardino P et al. (2012). Androgen Receptor in Tumor and Stroma in Conservatively Treated Prostate Cancer. LABORATORY INVESTIGATION. vol. 92, 215A-215A.
Stone SM, Cuzick J, Reid JE, Mesher D, Berney DM, Moller H, Speights VO, Fisher G et al.(2012). Cell cycle progression genes differentiate indolent from aggressive prostate cancer. EUROPEAN UROLOGY SUPPLEMENTS vol. 11, (1) E430-U942.
Berney D, Fisher G, Yang ZH, Moller H, Kudahetti S, Foster C, Reuter V, Scardino P et al. (2012). Molecular Factors Showing Multivariate Significance for Outcome in a Conservatively Treated Prostate Cancer Biopsy Cohort. MODERN PATHOLOGY. vol. 25, 192A-192A.
Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S et al.(2012). Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011. Ecancermedicalscience vol. 6,
10.3332/ecancer.2012.245
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman DAM, Kenter GG, Cuzick J et al.(2012). Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol vol. 13, (1) 78-88.
10.1016/S1470-2045(11)70296-0
Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevi¿ N, Scibior-Bentkowska D, Wu K, Ahmad AS et al.(2012). Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. Cancer Biomark vol. 11, (2-3) 75-88.
10.3233/CBM-2012-0266
Dowsett M, Lopez-Knowles E, Sidhu K, Pineda S, Cowens JW, Ferree S, Storhoff J, Schaper C et al. (2011). Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study. CANCER RESEARCH. vol. 71,
10.1158/0008-5472.SABCS11-S4-5
Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-Knowles E, Salter J et al.(2011). Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial. CANCER RESEARCH vol. 71,
10.1158/0008-5472.SABCS11-P1-06-02
Evans DGR, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Wilson M et al.(2011). Feasibility and Acceptability of Offering Breast Cancer Risk Estimation in the Context of the UK National Health Service Breast Cancer Screening Programme: A New Paradigm for Cancer Prevention. CANCER RESEARCH vol. 71,
10.1158/0008-5472.SABCS11-P4-11-07
Dowsett M, Afentakis M, Pineda S, Salter J, Howell A, Buzdar A, Forbes JF, Cuzick J (2011). Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study. CANCER RESEARCH. vol. 71,
10.1158/0008-5472.SABCS11-P2-02-01
Sestak I, Cuzick J, Dowsett M, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A et al.(2011). Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study. CANCER RESEARCH vol. 71,
10.1158/0008-5472.SABCS11-P2-12-09
Assi V, Warwick J, Cuzick J, Duffy SW(2011). Clinical and epidemiological issues in mammographic density. Nat Rev Clin Oncol vol. 9, (1) 33-40.
10.1038/nrclinonc.2011.173
Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M et al.(2011). Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males (vol 83, pg 1744, 2011). J MED VIROL vol. 83, (12) 2237-2237.
10.1002/jmv.22250
Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, Robles SC, Winkler JL et al.(2011). Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer vol. 21, (9) 1654-1663.
10.1097/IGC.0b013e3182288104
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S et al.(2011). Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol vol. 29, (33) 4365-4372.
10.1200/JCO.2011.35.3714
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL et al.(2011). Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst vol. 103, (22) 1656-1664.
10.1093/jnci/djr393
Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J(2011). Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol vol. 29, (32) 4266-4272.
10.1200/JCO.2011.35.5545
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E et al.(2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol vol. 29, (32) 4273-4278.
10.1200/JCO.2010.31.2835
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C et al.(2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. The Lancet vol. 378, (9804) 1707-1716.
10.1016/S0140-6736(11)61629-2
Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, Saunders NA, Nathan M et al.(2011). Human Papillomavirus Genotype Detection and Viral Load in Paired Genital and Urine Samples From Both Females and Males. J MED VIROL vol. 83, (10) 1744-1751.
10.1002/jmv.22167
Almonte M, Sasieni P, Cuzick J(2011). Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Pract Res Clin Obstet Gynaecol vol. 25, (5) 617-629.
10.1016/j.bpobgyn.2011.05.003
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM(2011). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (27)
10.1200/jco.2011.29.27_suppl.165
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM(2011). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. J Clin Oncol vol. 29, (27_suppl)
Cuzick J (2011). Cervix Cancer Vaccination. EUROPEAN JOURNAL OF CANCER. vol. 47, S15-S15.
10.1016/S0959-8049(11)70268-4
Evans G, Astley S, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M et al. (2011). Feasibility and acceptability of offering breast cancer risk estimation in the context of the UK National Health Service Breast Cancer Screening Programme: a new paradigm for cancer prevention. JOURNAL OF MEDICAL GENETICS. vol. 48, S41-S41.
Cuzick J, Glasier A, La Vecchia C, Maraganore DM, Negri E, Rossi M, Spector T, Trichopoulos D et al.(2011). Perimenopausal risk factors and future health. HUM REPROD UPDATE vol. 17, (5) 706-717.
10.1093/humupd/dmr020
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y et al.(2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet vol. 378, (9793) 771-784.
10.1016/S0140-6736(11)60993-8
Jeetle S, Yang ZH, Stankiewicz E, Fisher G, Cuzick J, Berney D(2011). Long-term outcome and neuroendocrine differentiation in conservatively treated prostate cancers. VIRCHOWS ARCH vol. 459, S59-S59.
Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S et al.(2011). Predictive algorithms for adjuvant therapy: TransATAC. Steroids vol. 76, (8) 777-780.
10.1016/j.steroids.2011.02.032
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Reid JE, Gutin A, Lanchbury JS et al.(2011). Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort. JOURNAL OF CLINICAL ONCOLOGY vol. 29, (15)
10.1200/jco.2011.29.15_suppl.4542
Cuzick JM, Fisher G, Berney D, Mesher D, Møller H, Reid JE, Gutin A, Lanchbury JS et al.(2011). Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort. J Clin Oncol vol. 29, (15_suppl)
O'Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G et al.(2011). Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer vol. 128, (10) 2373-2381.
10.1002/ijc.25570
Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RML(2011). Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst vol. 103, (9) 744-752.
10.1093/jnci/djr079
Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A et al.(2011). Preventive therapy for breast cancer: a consensus statement. Lancet Oncol vol. 12, (5) 496-503.
10.1016/S1470-2045(11)70030-4
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA et al.(2011). The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) vol. 35, (5) 714-727.
10.1038/ijo.2010.171
Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE(2011). Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol vol. 22, (4) 857-862.
10.1093/annonc/mdq541
Stankiewicz E, Prowse DM, Ng M, Cuzick J, Mesher D, Hiscock F, Lu Y-J, Watkin N et al.(2011). Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One vol. 6, (3)
10.1371/journal.pone.0017517
https://qmro.qmul.ac.uk/xmlui/handle/123456789/4726
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, for the ATAC/LATTE investigators(2011). 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply. Lancet Oncol vol. 12, (3)
10.1016/S1470-2045(11)70050-X
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators(2011). 10-year analysis of the ATAC trial: wrong conclusion? Reply. LANCET ONCOL vol. 12, (3) 217-217.
10.1016/S1470-2045(11)70050-X
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO et al.(2011). Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol vol. 12, (3) 245-255.
10.1016/S1470-2045(10)70295-3
Stankiewicz E, Mesher D, Ng M, Cuzick J, Prowse D, Hiscock F, Lu YJ, Lam W et al. (2011). Alternative Pathways of Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas. MODERN PATHOLOGY. vol. 24, 225A-226A.
Stankiewicz E, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Kudahetti S, Watkin N et al.(2011). The retinoblastoma protein/p16 INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma. Histopathology vol. 58, (3) 433-439.
10.1111/j.1365-2559.2011.03762.x
Vasiljevi¿ N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L et al.(2011). Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers vol. 30, (4) 151-161.
10.3233/DMA-2011-0790
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10491
Rajab R, Fisher G, Kattan MW, Foster CS, Møller H, Oliver T, Reuter V, Scardino PT et al.(2011). An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent. Mod Pathol vol. 24, (1) 58-63.
10.1038/modpathol.2010.182
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H et al.(2011). Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol vol. 12, (1) 21-29.
10.1016/S1470-2045(10)70266-7
Singh S, Cuzick J, Blake GM, Mesher D, Patel R, Truscott J, Coleman R, Howell A et al. (2011). One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study. BONE. vol. 48, S24-S24.
10.1016/j.bone.2010.10.064
Cuzick J(2010). Breast cancer prevention in the developing world. Breast Cancer Res vol. 12 Suppl 4,
10.1186/bcr2738
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Pineda S et al. (2010). Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. CANCER RESEARCH. vol. 70,
10.1158/0008-5472.SABCS10-S1-7
Ring AE, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J (2010). The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial. CANCER RESEARCH. vol. 70,
10.1158/0008-5472.SABCS10-P5-13-03
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators(2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. LANCET ONCOL vol. 11, (12) 1135-1141.
10.1016/S1470-2045(10)70257-6
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators(2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol vol. 11, (12) 1135-1141.
10.1016/S1470-2045(10)70257-6
Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW(2010). Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). Int J Cancer vol. 127, (11) 2639-2644.
10.1002/ijc.25278
Duffy SW, Mackay J, Thomas S, Anderson E, Evans DG, Fielder H, Fox R, Gray J et al.(2010). Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. LANCET ONCOL vol. 11, (12) 1127-1134.
10.1016/S1470.2045(10)70263.1
Rajab R, Fisher G, Kattan MW, Foster CS, Oliver T, Møller H, Reuter V, Scardino P et al.(2010). Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort. Virchows Arch vol. 457, (5) 547-553.
10.1007/s00428-010-0971-z
Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M et al.(2010). Significant differences in UK and US female bone density reference ranges. Osteoporos Int vol. 21, (11) 1871-1880.
10.1007/s00198-009-1153-1
Dowsett M, Pineda S, Cuzick J(2010). What Is the Value of the 21 Gene Recurrence Score in HER2-Negative Patients? Reply. J CLIN ONCOL vol. 28, (31) E648-E648.
10.1200/JCO.2010.31.2702
Cuzick JM, Fisher G, Berney D, Mesher D, Moller H, Lanchbury J, Gutin A, Stone S (2010). PROGNOSTIC VALUE OF A CELL CYCLE EXPRESSION PROFILE SCORE AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE CANCER. ANNALS OF ONCOLOGY. vol. 21, 63-63.
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J(2010). Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol vol. 28, (21) 3411-3415.
10.1200/JCO.2009.27.2021
Cuzick J(2010). Tamoxifen and the factor V Leiden mutation. J Natl Cancer Inst vol. 102, (13) 918-919.
10.1093/jnci/djq225
Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R et al.(2010). Performance of the Abbott RealTime High-Risk HPV Test in Women With Abnormal Cervical Cytology Smears. J MED VIROL vol. 82, (7) 1186-1191.
10.1002/jmv.21801
Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, Fentiman IS, George WD et al.(2010). A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer vol. 103, (1) 94-100.
10.1038/sj.bjc.6605718
Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JMA, Wardle J, UK Flexible Sigmoidoscopy Screenin(2010). Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial (vol 359, pg 1291, 2002). LANCET vol. 375, (9732) 2142-2142.
Cuzick J(2010). Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer Prev Res (Phila) vol. 3, (6) 689-691.
10.1158/1940-6207.CAPR-10-0096
Shan L, Ambroisine L, Clark J, Yáñez-Muñoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S et al.(2010). The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. Prostate Cancer Prostatic Dis vol. 13, (2) 117-125.
10.1038/pcan.2010.2
Tang G, Cuzick J, Wale C, Costantino JP, Crager M, Shak S, Wolmark N, Dowsett M et al. (2010). Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. JOURNAL OF CLINICAL ONCOLOGY. vol. 28,
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J et al.(2010). Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet vol. 375, (9726) 1624-1633.
10.1016/S0140-6736(10)60551-X
Cuzick J(2010). Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol vol. 117, (2 Suppl) S11-S14.
10.1016/j.ygyno.2010.01.025
Yao S, Bee A, Brewer D, Dodson A, Beesley C, Ke Y, Ambroisine L, Fisher G et al.(2010). PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. Genes Cancer vol. 1, (5) 444-464.
10.1177/1947601910376079
Atkin WS, Cuzick J, Duffy SW, Edwards R, Hart A, Kralj-Hans I, Northover JM, Wardle J et al. (2010). UK Flexible Sigmoidoscopy Screening Trial: Colorectal Cancer Incidence and Mortality Rates at 11 Years After a Single Screening Examination. GASTROENTEROLOGY. vol. 138, S53-S53.
Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, Menon U, Hulman G et al.(2010). Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer vol. 102, (9) 1405-1410.
10.1038/sj.bjc.6605619
https://qmro.qmul.ac.uk/xmlui/handle/123456789/30445
Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A et al.(2010). Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol vol. 28, (11) 1829-1834.
10.1200/JCO.2009.24.4798
Cuzick J, Castañón A, Sasieni P(2010). Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer vol. 102, (5) 933-939.
10.1038/sj.bjc.6605528
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12428
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S et al.(2010). Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol vol. 11, (3) 249-257.
10.1016/S1470-2045(09)70360-2
Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P et al.(2010). Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer vol. 102, (4) 678-684.
10.1038/sj.bjc.6605554
Thomsen MK, Ambroisine L, Wynn S, Cheah KSE, Foster CS, Fisher G, Berney DM, Møller H et al.(2010). SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res vol. 70, (3) 979-987.
10.1158/0008-5472.CAN-09-2370
Stankiewicz E, Prowse DM, Cuzick J, Ambroisine L, Kudahetti S, Watkin N, Corbishley C, Berney DM (2010). The RB/p16 Pathway but Not p53 Is Disrupted by High Risk HPV in Penile Squamous Cell Carcinoma. MODERN PATHOLOGY. vol. 23, 221A-221A.
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M et al.(2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol vol. 28, (3) 509-518.
10.1200/JCO.2009.23.1274
Sasieni P, Castañón A, Cuzick J(2010). ACOG guidelines on cervical screening: a step in the right direction. J Med Screen vol. 17, (2) 55-56.
10.1258/jms.2010.010054
Cuzick J(2010). Controversies in design and interpretation of adjuvant clinical trials. Cancer Invest vol. 28 Suppl 1, 28-34.
10.3109/07357907.2010.501633
Harvie M, Pegington M, Cuzick J, Frystyk J, Flyvbjerg A, Jebb S, Mattson M, Howell A (2010). Effect of intermittent versus continuous energy restriction on weight loss and breast cancer risk biomarkers. BREAST CANCER RESEARCH. vol. 12, S9-S10.
10.1186/bcr2525
Kudahetti SC, Fisher G, Ambroisine L, Prowse D, Kattan MW, Foster CS, Møller H, Oliver T et al.(2010). Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology vol. 42, (6) 519-523.
10.3109/00313025.2010.508788
Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, Robertson J, Swain S et al.(2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute - Monographs vol. 41, 162-177.
10.1093/jncimonographs/lgq039
Distler W, Canzler U, Duffy SR, Howell A, Cuzick J, Baum M(2010). Undesirable Gynaecological and Operative Interventions during Treatment of Breast Cancer with Anastrozole and Tamoxifen. GEBURTSH FRAUENHEILK vol. 70, (1) 57-61.
10.1055/s-0029-1240720
Sasieni P, Castañon A, Cuzick J(2010). What is the right age for cervical cancer screening?. Womens Health (Lond) vol. 6, (1) 1-4.
10.2217/whe.09.69
Cuzick J (2009). Advances in Preventive Therapy. CANCER RESEARCH. vol. 69, 482S-482S.
Cuzick J, Sestak I, Pinder SE, Ellis IO, Hackshaw A, Bundred NJ, Forbes JF, Bishop H et al. (2009). Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results front the UK/ANZ DCIS Trial in Women with Locally Excised DCIS. CANCER RESEARCH. vol. 69, 493S-493S.
Stone J, Warren RML, Pinney E, Warwick J, Cuzick J(2009). Determinants of percentage and area measures of mammographic density. Am J Epidemiol vol. 170, (12) 1571-1578.
10.1093/aje/kwp313
Sestak I, Distler W, Forbes JF, Howell A, Cuzick J (2009). Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer - A Retrospective Exploratory Analysis from the ATAC Trial. CANCER RESEARCH. vol. 69, 553S-553S.
Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A et al. (2009). Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score - Results from TransATAC. CANCER RESEARCH. vol. 69, 503S-503S.
Cuzick J (2009). Use of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: An Overview of the Randomized Trials. CANCER RESEARCH. vol. 69, 532S-532S.
Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE(2009). How to evaluate emerging technologies in cervical cancer screening?. Int J Cancer vol. 125, (11) 2489-2496.
10.1002/ijc.24774
Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM(2009). EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer vol. 125, (10) 2246-2255.
10.1002/ijc.24634
Sestak I, Sapunar F, Cuzick J(2009). Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol vol. 27, (30) 4961-4965.
10.1200/JCO.2009.22.0236
Foster CS, Dodson AR, Ambroisine L, Fisher G, Møller H, Clark J, Attard G, De-Bono J et al.(2009). Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer vol. 101, (7) 1137-1144.
10.1038/sj.bjc.6605227
Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S et al.(2009). Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol vol. 56, (4) 584-591.
10.1016/j.eururo.2009.07.018
Sasieni P, Castle PE, Cuzick J(2009). Further analysis of the ARTISTIC trial. Lancet Oncol vol. 10, (9) 841-842.
10.1016/S1470-2045(09)70246-3
Elliott P, Cuzick J, English D, Stern R(2009). Geographical and Environmental Epidemiology: Methods for Small Area Studies.
Stankiewicz E, Kudahetti SC, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Watkin N et al.(2009). HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol vol. 22, (9) 1160-1168.
10.1038/modpathol.2009.77
Elliott P, Cuzick J, English D, Stern R(2009). Introductory remarks by the editors.
Alexander FE, Cuzick J(2009). Methods for the assessment of disease clusters. Geographical and Environmental Epidemiology: Methods for Small Area Studies,
Cuzick J, Elliott P(2009). Small-area studies: Purpose and methods. Geographical and Environmental Epidemiology: Methods for Small Area Studies,
Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R et al.(2009). Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast vol. 18 Suppl 2, S1-11.
10.1016/S0960-9776(09)70002-5
Sasieni P, Castanon A, Cuzick J(2009). Screening and adenocarcinoma of the cervix. INT J CANCER vol. 125, (3) 525-529.
10.1002/ijc.24410
Sasieni P, Castanon A, Cuzick J(2009). Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ vol. 339,
10.1136/bmj.b2968
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9993
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C et al.(2009). American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Oncology Practice vol. 5, (4) 196-199.
10.1200/JOP.0948502
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C et al.(2009). American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol vol. 27, (19) 3235-3258.
10.1200/JCO.2008.20.5179
Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Møller H, Kattan MW et al.(2009). p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int vol. 104, (1) 20-24.
10.1111/j.1464-410X.2009.08407.x
Arbyn M, Cuzick J(2009). International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. Cancer Lett vol. 278, (1) 1-2.
10.1016/j.canlet.2008.09.002
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C et al.(2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol vol. 10, (5) 501-507.
10.1016/S1470-2045(09)70035-X
Kerkhot M, Roobol MJ, Steyerberg EW, Cuzick J, Schroder FH (2009). SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION. JOURNAL OF UROLOGY. vol. 181, 233-233.
10.1016/S0022-5347(09)60662-5
Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J et al.(2009). Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer vol. 100, (6) 888-893.
10.1038/sj.bjc.6604951
Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J et al.(2009). Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst vol. 101, (6) 384-398.
10.1093/jnci/djp018
Howell A, ForbeS J, Cuzick J, ATAC Investigators(2009). Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population. BREAST vol. 18, S51-S51.
10.1016/S0960-9776(09)70162-6
Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX et al.(2009). Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer vol. 124, (3) 516-520.
10.1002/ijc.24010
Ingle JN, Dowsett M, Cuzick J, Davies C (2009). Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. CANCER RESEARCH. vol. 69, 66S-66S.
Cuzick J, Warwick J, Pinney L, Warren R, Cawthorn S, Howell A, Duffy S (2009). Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-1. CANCER RESEARCH. vol. 69, 77S-78S.
Sestak I, Cuzick J (2009). Characteristics of carpal-tunnel syndrome in the ATAC trial. CANCER RESEARCH. vol. 69, 326S-326S.
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R et al. (2009). Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. CANCER RESEARCH. vol. 69, 75S-76S.
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Jebb S, Mattson M, Howell A (2009). The effect of intermittent versus continuous energy restriction on biomarkers of breast cancer. CANCER RESEARCH. vol. 69, 95S-96S.
Duffy SR, Distler W, Howell A, Cuzick J, Baum M (2009). A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol. vol. 200, 80.e1-80.e7.
10.1016/j.ajog.2008.07.062
Oliver T, Lorinez A, Cuzick J (2009). Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies. Recent Results Cancer Res. vol. 181, 195-205.
10.1007/978-3-540-69297-3_18
Howell A, Cuzick J(2009). Risk factors. Introduction to Session 1. Breast Cancer Res vol. 11 Suppl 3,
10.1186/bcr2421
Rajab R, Fisher G, Ambroisine L, Foster CS, Moller H, Kattan M, Reuter V, Scardino P et al. (2009). The Predictive Power of Prostate Cancer Extent Measurements in a Large Watchful Waiting Cohort. LABORATORY INVESTIGATION. vol. 89, 190A-190A.
Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group(2008). Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol vol. 9, (12) 1143-1148.
10.1016/S1470-2045(08)70259-6
Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, Cuzick J(2008). Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. BRIT J CANCER vol. 99, (10) 1572-1578.
10.1038/sj.bjc.6604759
Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R et al.(2008). Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev vol. 17, (11) 3033-3042.
10.1158/1055-9965.EPI-08-0508
Clark J, Attard G, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S et al.(2008). ETS GENE TRANSLOCATIONS AND PROSTATE CANCER PROGNOSIS. ANTICANCER RES vol. 28, (6B) 4155-4156.
Cuzick J(2008). Hormone replacement therapy and the risk of breast cancer. Eur J Cancer vol. 44, (16) 2344-2349.
10.1016/j.ejca.2008.07.041
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, De Sanjose S, Naucler P et al.(2008). Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ vol. 337, (7676) 969-972.
10.1136/bmj.a1662
Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, de Sanjose S, Naucler P et al.(2008). Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ vol. 337,
10.1136/bmj.a1754
Kudahetti S, Fisher G, Ambroidine I, Kattan M, Foster C, Oliver T, Moller H, Reuter V et al. (2008). Cell-cycle proteins as biomarkers in clinically localised prostate cancer patients managed conservatively-results from the trans-atlantic prostate group. HISTOPATHOLOGY. vol. 53, 279-280.
Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ(2008). Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol vol. 9, (10) 953-961.
10.1016/S1470-2045(08)70207-9
Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G et al.(2008). Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol vol. 9, (10) 937-945.
10.1016/S1470-2045(08)70208-0
Oliver T, Lorincz A, Cuzick J(2008). CHEMO-PREVENTION OF: PROSTATE CANCER: THE RATIONALE BEHIND DESIGN OF PILOT STUDIES. ANTICANCER RES vol. 28, (5C) 3428-3429.
Cuzick JM (2008). DETERMINING THE OPTIMAL TIMING AND DURATION OF THE USE OF AN AROMATASE INHIBITOR (AI) IN THE ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE (HR plus ) BREAST CANCER (BC) USING MODELLING ANALYSES. ANNALS OF ONCOLOGY. vol. 19, 87-87.
Cuzick J(2008). IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther vol. 8, (9) 1377-1385.
10.1586/14737140.8.9.1377
Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group(2008). Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol vol. 9, (9) 866-872.
10.1016/S1470-2045(08)70182-7
Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, Dillner J, Meijer CJLM(2008). Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine vol. 26 Suppl 10, K29-K41.
10.1016/j.vaccine.2008.06.019
Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim Y-T, Konno R, Parkin DM, Qiao Y-L et al.(2008). Recommendations for cervical cancer prevention in Asia Pacific. Vaccine vol. 26 Suppl 12, M89-M98.
10.1016/j.vaccine.2008.06.020
Cuzick J(2008). Use of LHRH-agonists as adjuvant therapy for breast cancer. Expert Opin Ther Targets vol. 12, (8) 1065-1071.
10.1517/14728222.12.8.1065
Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, Reid A, Edwards S et al.(2008). Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer vol. 99, (2) 314-320.
10.1038/sj.bjc.6604472
Cuzick J(2008). Primary endpoints for randomised trials of cancer therapy. Lancet vol. 371, (9631) 2156-2158.
10.1016/S0140-6736(08)60933-2
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, ATAC Trialists Grp (2008). ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion. BREAST CANCER RESEARCH AND TREATMENT. vol. 109, 590-590.
Buzdar AU, Cuzick J (2008). Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up. JOURNAL OF CLINICAL ONCOLOGY. vol. 26,
10.1200/jco.2008.26.15_suppl.552
Grimison PS, Coates AS, Forbes JF, Cuzick J, Furnival C, Craft PS, Snyder RD, Thornton RM et al. (2008). Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1). JOURNAL OF CLINICAL ONCOLOGY. vol. 26,
10.1200/jco.2008.26.15_suppl.1516
Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G et al.(2008). Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer vol. 122, (10) 2294-2300.
10.1002/ijc.23339
Cuzick J(2008). Review of Swedish cervical cancer screening program demonstrates effectiveness and room for improvement. J NATL CANCER I vol. 100, (9) 602-602.
Cuzick J(2008). Routine audit of large-scale cervical cancer screening programs. J Natl Cancer Inst vol. 100, (9) 605-606.
10.1093/jnci/djn131
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D et al.(2008). Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst vol. 100, (7) 492-501.
10.1093/jnci/djn065
Cuzick J(2008). Aromatase inhibitors in early breast-cancer treatment: The story so far. Breast vol. 17 Suppl 3, S2-S8.
10.1016/j.breast.2007.12.002
Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walkers M, Cuzick J (2008). Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis. EJC SUPPLEMENTS. vol. 6, 216-216.
10.1016/S1359-6349(08)70880-2
Cuzick J (2008). Optimal timing and duration of the use of an aromatase inhibitor (AI) in the adjuvant treatment of postmenopausal hormone receptor-positive (HR+) breast cancer (BC). EJC SUPPLEMENTS. vol. 6, 121-121.
10.1016/S1359-6349(08)70562-7
Sestak I, Forbes JF, Edwards R, Howell A, Cuzick J (2008). Timing and severity of prominent side effects of anastrozole and tamoxifen. EJC SUPPLEMENTS. vol. 6, 71-71.
10.1016/S1359-6349(08)70389-6
Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P et al.(2008). Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene vol. 27, (14) 1993-2003.
10.1038/sj.onc.1210843
Franco EL, Cuzick J(2008). Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine vol. 26 Suppl 1, A16-A23.
10.1016/j.vaccine.2007.11.069
Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW et al. (2008). Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. vol. 26, 1051-1057.
10.1200/JCO.2007.11.0726
Oliver RTD, Lorincz A, Cuzick J (2008). Prostate cancer prevention by short-term antiandrogens: A novel strategy. EJC SUPPLEMENTS. vol. 6, 32-32.
10.1016/S1359-6349(08)70224-6
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J et al.(2008). Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol vol. 26, (7) 1059-1065.
10.1200/JCO.2007.12.9437
Cuzick J (2008). Use of aromatase inhibitors in breast cancer prevention. EJC SUPPLEMENTS. vol. 6, 21-21.
10.1016/S1359-6349(08)70213-1
Eastham JA, Kattan MW, Fearn P, Fisher G, Berney DM, Oliver T, Foster CS, Moller H et al.(2008). Local progression among men with conservatively treated localized prostate cancer: Results from the transatlantic prostate group. EUR UROL vol. 53, (2) 347-354.
10.1016/j.eururo.2007.05.015
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS et al.(2008). Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene vol. 27, (3) 253-263.
10.1038/sj.onc.1210640
Cuzick J(2008). Assessing risk for breast cancer. Breast Cancer Res vol. 10 Suppl 4,
10.1186/bcr2173
Cuzick J(2008). Chemoprevention of breast cancer. Breast Cancer vol. 15, (1) 10-16.
10.1007/s12282-007-0006-z
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M(2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol vol. 9, (1) 45-53.
10.1016/S1470-2045(07)70385-6
Singh S, Cuzick J, Ferguson S, Blake G, Truscott J, Coleman R, Eastel R, Howell A (2008). Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). CANCER TREATMENT REVIEWS. vol. 34, S53-S54.
10.1016/j.ctrv.2008.03.037
Eastell R, Adams JE, Clack G, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann M et al.(2008). Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial. CALCIFIED TISSUE INT vol. 82, S84-S84.
Berney DM, Gopalan A, Kudahetti S, Ambroisine L, Fisher G, Kattan M, Moller H, Foster C et al. (2008). KI-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer. LABORATORY INVESTIGATION. vol. 88, 148A-148A.
Berney DM, Gopalan A, Kudahetti S, Ambroisine L, Fisher G, Kattan M, Moller H, Foster C et al. (2008). Ki-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer. MODERN PATHOLOGY. vol. 21, 148A-148A.
Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, Moller H, Reuter V et al.(2008). Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. CANCER vol. 112, (1) 69-74.
10.1002/cncr.23106
Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R (2008). Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol. vol. 617, 201-211.
10.1007/978-0-387-69080-3_19
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A (2008). The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. BREAST CANCER RESEARCH. vol. 10, S27-S28.
10.1186/bcr1937
Duffy SW, Nagtegaal ID, Astley SM, Gillan MGC, McGee MA, Boggis CRM, Wilson M, Beetles UM et al.(2008). Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. Breast Cancer Res vol. 10, (4)
10.1186/bcr2123
Giorgi-Rossi P, Segnan N, Zappa M, Naldoni C, Zorzi M, Confortini M, Merito M, Cuzick J et al.(2007). The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer vol. 121, (12) 2729-2734.
10.1002/ijc.23055
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M, ATAC Trialists Grp (2007). ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion. BREAST CANCER RESEARCH AND TREATMENT. vol. 106, S12-S13.
Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R, Howell A (2007). Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). BREAST CANCER RESEARCH AND TREATMENT. vol. 106, S9-S9.
Cuzick J (2007). Hormone replacement therapy and breast cancer - a summary of results from other studies. BREAST CANCER RESEARCH AND TREATMENT. vol. 106, S3-S3.
Cuzick J (2007). Hot flushes and the risk of recurrence - retrospective, exploratory results from the ATAC trial. BREAST CANCER RESEARCH AND TREATMENT. vol. 106, S108-S108.
Berney DM, Fisher G, Kattan MW, Oliver RTD, Møller H, Fearn P, Eastham J, Scardino P et al.(2007). Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int vol. 100, (6) 1240-1244.
10.1111/j.1464-410X.2007.07199.x
Eastell R, Coleman R, Mansel R, Bianco A, Nagykalnai T, Cuzick J, ATAC Trialists Grp (2007). The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial. BREAST CANCER RESEARCH AND TREATMENT. vol. 106, S109-S109.
Berney DM, Fisher G, Kattan MW, Oliver RTD, Møller H, Fearn P, Eastham J, Scardino P et al.(2007). Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome. Histopathology vol. 51, (4) 452-457.
10.1111/j.1365-2559.2007.02819.x
Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, Naldoni C, Segnan N et al.(2007). The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol Oncol vol. 107, (1 Suppl 1) S230-S232.
10.1016/j.ygyno.2007.07.021
Cuzick J(2007). Adjusting for non-compliance and contamination in randomised clinical trials (vol 16, pg 1017, 1997). STAT MED vol. 26, (20) 3821-3821.
10.1002/sim.2922
Sestak I, Edwards R, Howell A, Cuzick J (2007). Effect of tamoxifen on serum lipid levels in women at increased risk of breast cancer. EJC SUPPLEMENTS. vol. 5, 31-31.
10.1016/S1359-6349(07)71791-3
Almonte M, Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P(2007). Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer vol. 121, (4) 796-802.
10.1002/ijc.22757
Cuzick J(2007). The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther vol. 7, (8) 1089-1094.
10.1586/14737140.7.8.1089
Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P et al.(2007). Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ vol. 335, (7609)
10.1136/bmj.39196.740995.BE
Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C, Lous JJ, Cuzick J, Schröder FH(2007). Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial. Prostate vol. 67, (10) 1053-1060.
10.1002/pros.20606
Cuzick J, Sasieni P, Howell A (2007). Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?. JOURNAL OF CLINICAL ONCOLOGY. vol. 25,
Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF et al.(2007). Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer vol. 14, (2) 169-187.
10.1677/ERC-06-0045
LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R(2007). Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet vol. 369, (9574) 1711-1723.
10.1016/S0140-6736(07)60778-8
Cuzick J(2007). Mammographic breast density. N Engl J Med vol. 356, (18) 1885-1887.
10.1056/nejmc070404
Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, Oliver T(2007). International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int vol. 99, (5) 1056-1065.
10.1111/j.1464-410X.2007.06770.x
Donovan MJ, Hamann S, Clayton M, Teverovskiy M, Vengrenyuk Y, Khan F, Eggener SE, Reuter VE et al. (2007). Predicting disease specific survival at the time of diagnosis utilizing clinical variables integrated with quantitative immunofluorescence. JOURNAL OF UROLOGY. vol. 177, 590-590.
10.1016/S0022-5347(18)31962-1
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators(2007). Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst vol. 99, (4) 272-282.
10.1093/jnci/djk049
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A et al.(2007). HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer vol. 43, (3) 476-480.
10.1016/j.ejca.2006.11.013
Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H(2007). Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer vol. 7,
10.1186/1471-2407-7-9
Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J(2007). The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer vol. 96, (1) 110-117.
10.1038/sj.bjc.6603512
Cuzick J(2007). Aromatase inhibitors in the treatment of breast cancer: Results of the ATAC trial. Nature Clinical Practice Oncology vol. 4, (SUPPL. 1)
10.1038/ncponc0858
Cuzick J(2007). Comparison between initial therapy with an aromatase inhibitor and sequential treatment after tamoxifen. Nature Clinical Practice Oncology vol. 4, (SUPPL. 1)
10.1038/ncponc0859
Sestk I, Edwards R, Howell A, Cuzick J (2007). Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial. BREAST CANCER RESEARCH. vol. 9,
10.1186/bcr1723
Cuzick J, Sasieni P, Myles J, Tyrer J(2007). Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination. J ROY STAT SOC B vol. 69, 565-588.
10.1111/j.1467-9868.2007.00600.x
Howell A, Clarke RB, Evans G, Bundred N, Cuzick J, Santen R, Allred C(2007). Estrogen deprivation for breast cancer prevention. Recent Results Cancer Res vol. 174, 151-167.
10.1007/978-3-540-37696-5_13
Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, Wardle J, Altman DG et al.(2007). Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen vol. 14, (1) 34-42.
10.1258/096914107780154486
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39547
Cuzick J, Cafferty FH, Edwards R, Møller H, Duffy SW(2007). Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial. J Med Screen vol. 14, (4) 178-185.
10.1258/096914107782912059
Chapman M, Howelli A, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Harvie M(2007). The effect of intermittent v. chronic energy restriction on weight loss in premenopausal women: preliminary results from a randomised pilot trial to reduce breast cancer risk. P NUTR SOC vol. 66, 99A-99A.
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebbs S, Parfitt G, Howell A (2007). The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: A randomized pilot trial. JOURNAL OF NUTRITION. vol. 137, 283S-283S.
Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialistsa9 Group(2006). Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat vol. 100, (3) 273-284.
10.1007/s10549-006-9260-6
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V et al.(2006). Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer vol. 95, (9) 1186-1194.
10.1038/sj.bjc.6603411
Cuzick J(2006). Chemoprevention of breast cancer. Womens Health (Lond) vol. 2, (6) 853-861.
10.2217/17455057.2.6.853
Cox T, Cuzick J (2006). HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol. vol. 103, 8-11.
10.1016/j.ygyno.2006.07.030
Rajkumar T, Cuzick J, Appleby P, Barnabas R, Beral V, Berrington De González A, Bull D, Canfell K et al.(2006). Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. International Journal of Cancer vol. 119, (5) 1108-1124.
10.1002/ijc.21953
Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P et al.(2006). Overview of the European and North American studies on HPV testing in primary cervical cancer screening. INT J CANCER vol. 119, (5) 1095-1101.
10.1002/ijc.21955
Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J(2006). Chapter 10: New dimensions in cervical cancer screening. Vaccine vol. 24 Suppl 3, S3/90-S3/97.
10.1016/j.vaccine.2006.05.122
Franco EL, Cuzick J, Hildesheim A, de Sanjosé S(2006). Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine vol. 24 Suppl 3, S3/171-S3/177.
10.1016/j.vaccine.2006.05.061
Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC(2006). Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine vol. 24 Suppl 3, S3/242-S3/249.
10.1016/j.vaccine.2006.06.038
Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A(2006). Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine vol. 24 Suppl 3, S3/251-S3/261.
10.1016/j.vaccine.2006.06.064
Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J (2006). Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. vol. 24, 3991-3996.
10.1200/JCO.2005.04.3745
Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J et al.(2006). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol vol. 7, (8) 633-643.
10.1016/S1470-2045(06)70767-7
Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P(2006). Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin vol. 22, (8) 1575-1585.
10.1185/030079906X120940
Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group(2006). Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res vol. 21, (8) 1215-1223.
10.1359/jbmr.060508
Buzdar AU, Guastalla J-P, Nabholtz J-M, Cuzick J, ATAC Trialists' Group(2006). Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer vol. 107, (3) 472-480.
10.1002/cncr.22042
Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C et al.(2006). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol vol. 7, (7) 547-555.
10.1016/S1470-2045(06)70731-8
Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A et al.(2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst vol. 98, (11) 765-774.
10.1093/jnci/djj209
Cuzick J, Forbes JF, Howell A(2006). Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst vol. 98, (9)
10.1093/jnci/djj167
Buzdar AU, Baum M, Cuzick J(2006). Letrozole or tamoxifen in early breast cancer. N Engl J Med vol. 354, (14) 1528-1530.
10.1056/NEJMc060194
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M, Buzdar A(2006). Progesterone receptor and human epidermal growth factor receptor 2 status: An independent influence on the efficacy of endocrine therapy in breast cancer? Reply. J CLIN ONCOL vol. 24, (9) 1482-1482.
10.1200/JCO.2005.05.1623
Houssami N, Cuzick J, Dixon JM(2006). The prevention, detection, and management of breast cancer. Med J Aust vol. 184, (5) 230-234.
10.5694/j.1326-5377.2006.tb00208.x
Cuzick J, Sasieni P, Howell A(2006). Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer vol. 94, (4) 460-464.
10.1038/sj.bjc.6602964
Buzdar AU, Cuzick J (2006). Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res. vol. 12, 1037s-1048s.
10.1158/1078-0432.CCR-05-2458
Cuzick J(2006). Keynote comment: Chemoprevention of cancer--time to catch up with the cardiologists. Lancet Oncol vol. 7, (2) 98-99.
10.1016/S1470-2045(06)70547-2
Howell A, Cuzick J(2006). Vascular effects of aromatase inhibitors: Data from clinical trials (vol 95, pg 143, 2005). J STEROID BIOCHEM vol. 98, (2-3) 180-180.
10.1016/j.jsbmb.2005.11.003
Cuzick J, Wale C, ATAC Trialists' Group (2006). A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years' treatment. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S24-S24.
Ronco G, Segnan N, Confortini M, Giorgi-Rossi P, Vettorazzi M, Naldoni C, Palma PD, Cuzick J(2006). A randomises trial on HPV testing for primary cervical screening: Data at recruitment. EUR J EPIDEMIOL vol. 21, 53-53.
Cuzick J(2006). Bone versus breast density. Breast Cancer Res vol. 8, (3)
10.1186/bcr1407
Gao JN, Forbes JF, Warren RML, Cuzick J, Howell A, D'Este C, Warren-Forward H (2006). Change in marnmographic density after cessation of tamoxifen: results from international breast cancer intervention study I (IBIS I). BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S56-S56.
Sestak I, Forbes J, Roseann K, Edwards R, Howell A, Cuzick J (2006). Comparison of side-effect profiles during active treatment versus follow-up in the IBIS-1 tamoxifen prevention study. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S55-S55.
Singh S, Richmond B, Howell A, Cuzick J (2006). Effect of anastrozole on cholesterol fractions in postmenopausal women with high risk of breast cancer: results from IBIS-II breast cancer prevention study. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S57-S57.
Harvie M, Chapman M, Cuzick J, Flyvbjerg A, Hopwood P, Jebb S, Parfitt G, Howell A (2006). Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: A randomised pilot trial. BREAST CANCER RESEARCH. vol. 8, S14-S14.
10.1186/bcr1584
Berney DM, Fisher G, Cuzick J, Scardino P, Kattan M, Reuter V, Foster CS (2006). Gleason score and survival in conservatively treated localised prostate cancer. MODERN PATHOLOGY. vol. 19, 130A-130A.
Cuzick J, IBIS Investigators (2006). Long term efficacy of tamoxifen for chemoprevention - results of the IBIS-I study. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S16-S17.
Berney DM, Cuzick J, Scardino P, Fisher G, Kattan M, Foster CS, Reuter V (2006). Pitfalls in the diagnosis of prostate cancer. A review of 1861 cases. LABORATORY INVESTIGATION. vol. 86, 130A-130A.
Cuzick J, Warren R, Pinney L, Warwick J, Howell A (2006). The effect of anastrozole, tamoxifen or a combination of both drugs on mammographic breast density in post menopausal women with breast cancer. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S224-S224.
Cuzick J, LHRH-Agonist Overview Group (2006). The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomized trials. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S10-S10.
Singh S, Howell A, Cuzick J (2006). Vit D levels among patients with Arthralgia: results from IBIS-II breast cancer prevention study. BREAST CANCER RESEARCH AND TREATMENT. vol. 100, S61-S61.
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K et al.(2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. LANCET vol. 366, (9503) 2087-2106.
10.1016/S0140-6736(05)67887-7
Buzdar AU, Cuzick J(2005). Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol vol. 23, (33) 8544-8546.
10.1200/JCO.2005.03.7416
Forbes JF, Cuzick J(2005). Systemic adjuvant therapies for early breast cancer: 15-year results for recurrence and survival. Med J Aust vol. 183, (9) 447-448.
10.5694/j.1326-5377.2005.tb07120.x
Cuzick J (2005). Breast cancer prevention - Beyond tamoxifen. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. vol. 14, 2804S-2804S.
Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M(2005). Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol vol. 23, (30) 7512-7517.
10.1200/JCO.2005.01.4829
Cuzick J(2005). Can HPV testing challenge the PAP smear?. EJC SUPPL vol. 3, (2) 9-9.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn H, Albain KS, Bergh J et al.(2005). Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. ANN ONCOL vol. 16, (10) 1569-1583.
10.1093/annonc/mdi326
Cuzick J(2005). The implications of delaying the start of aromatase inhibitor (AI) therapy. EJC SUPPL vol. 3, (2) 109-110.
Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A et al.(2005). A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer vol. 41, (14) 2141-2149.
10.1016/j.ejca.2005.04.038
Bataille V, Boniol M, De Vries E, Severi G, Brandberg Y, Sasieni P, Cuzick J, Eggermont A et al. (2005). Sunbed use and melanoma: a multi-centre case-control study of melanoma in Europe. BRITISH JOURNAL OF DERMATOLOGY. vol. 153, 2-2.
Baum M, Cuzick J, Howell A, Buzdar A, Demicheli R, Greco M, Retsky M, Hrushesky B et al. (2005). An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database. JOURNAL OF CLINICAL ONCOLOGY. vol. 23, 31S-31S.
Kattan MW, Cuzick J, Scardino PT, Transatlantic Prostate Grp (2005). Natural history of prostate cancer in a large cohort of untreated patients in the United Kingdom. JOURNAL OF CLINICAL ONCOLOGY. vol. 23, 381S-381S.
Cuzick J, Howell A (2005). Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 23, 43S-43S.
Cuzick J, Duffy S, Tyrer J(2005). A breast cancer prediction model - Authors' reply. STAT MED vol. 24, (10) 1612-1612.
10.1002/sim.2014
Cuzick J(2005). Interaction of statisticians with DMCs. Stat Med vol. 24, (10)
10.1002/sim.2027
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K et al.(2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. LANCET vol. 365, (9472) 1687-1717.
10.1016/S0140-6736(05)66544-0
Howell A, Cuzick J(2005). Vascular effects of aromatase inhibitors: Data from clinical trials. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY vol. 95, (1-5) 143-149.
10.1016/j.jsbmb.2005.04.005
Cuzick J(2005). Forest plots and the interpretation of subgroups. Lancet vol. 365, (9467)
10.1016/S0140-6736(05)61026-4
Cuzick J(2005). Anastrozole. DRUG TODAY vol. 41, (4) 227-239.
10.1358/dot.2005.41.4.908563
Cuzick J(2005). Radiotherapy for breast cancer. J NATL CANCER I vol. 97, (6) 406-407.
10.1093/jnci/dji086
Cuzick J(2005). Aromatase inhibitors for breast cancer prevention. J CLIN ONCOL vol. 23, (8) 1636-1643.
10.1200/JCO.2005.11.027
Tyrer J, Duffy SW, Cuzick J(2005). A breast cancer prediction model incorporating familial and personal risk factors (vol 23, pg 1111, 2004). STAT MED vol. 24, (1) 156-156.
10.1002/sim.1913
Cuzick J (2005). Chemoprevention: beyond tamoxifen. BREAST CANCER RESEARCH. vol. 7, S9-S9.
10.1186/bcr1219
Cuzick J, Howell A, Forbes J(2005). Early stopping of clinical trials. BREAST CANCER RES vol. 7, (5) 181-183.
10.1186/bcr1280
Shaw GL, Cuzick J, Prapotnich D, Spry N, Tucker S, Zerbib M, Goldenberg SL, Malone S et al. (2005). International study of the use of intermittent hormone therapy for cancer of the prostate (ISICAP). ANNALS OF ONCOLOGY. vol. 16, 294-294.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I et al.(2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. LANCET vol. 365, (9453) 60-62.
10.1016/S0140-6736(04)17666-6
SASIENI P, Cuzick J(2005). Screening. Introduction to the cellular and molecular biology of cancer., Editors: Knowles, M, Selby, P, Edition. 4th, Oxford University Press (Oxford),
CUZICK JM(2005). Testing Times (Book reviews on 'Should I be tested for Cancer?' by H Gilbert Welch). Lancet Oncology vol. 6, 12-13.
Sestak I, Kealy R, Edwards R, Cuzick J (2005). The influence of hormone replacement therapy (HRT) on tamoxifen induced vasomotor symptoms. BREAST CANCER RESEARCH AND TREATMENT. vol. 94, S11-S12.
Terry G, Ho L, Londesborough P, Cross P, Lopes A, Monaghan J, Cuzick J(2004). The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions. Br J Cancer vol. 91, (12) 2056-2062.
10.1038/sj.bjc.6602253
Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A(2004). Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol vol. 22, (21) 4261-4271.
10.1200/JCO.2004.08.029
Locker GY, Sainsbury JR, Cuzick J, ATAC Trialists' Group(2004). Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Cancer vol. 101, (4) 735-740.
10.1002/cncr.20435
Sainsbury R, Locker G, Cuzick J, ATAC Trialists Grp (2004). The use of adjuvant chemotherapy in the ATAC trial: Nationality correlates with the use of chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. vol. 22, 26S-26S.
Atkin W, Rogers P, Cardwell C, Cook C, Cuzick J, Wardle J, Edwards R(2004). Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. Gastroenterology vol. 126, (5) 1247-1256.
10.1053/j.gastro.2004.01.023
Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW(2004). Tamoxifen and breast density in women at increased risk of breast cancer. J NATL CANCER I vol. 96, (8) 621-628.
10.1093/jnci/djh106
Tyrer J, Duffy SW, Cuzick J(2004). A breast cancer prediction model incorporating familial and personal risk factors. Stat Med vol. 23, (7) 1111-1130.
10.1002/sim.1668
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M et al.(2004). Adjuvant use of anastrozole in breast cancer. J Clin Oncol vol. 22, (8) 1524-1526.
10.1200/JCO.2004.99.165
Sasieni P, Adams J, Cuzick J(2004). Reply: The value of case-control audits of screening. BRIT J CANCER vol. 90, (5) 1109-1110.
10.1038/sj.bjc.6601599
Bataille V, Winnett A, Sasieni P, Bishop JAN, Cuzick J(2004). Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study. EUR J CANCER vol. 40, (3) 429-435.
10.1016/j.ejca.2003.09.030
Fielder HM, Warwick J, Brook D, Gower-Thomas K, Cuzick J, Monypenny I, Duffy SW(2004). A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen vol. 11, (4) 194-198.
10.1258/0969141042467304
Cuzick J(2004). Chemoprevention of breast cancer. BIOMED PHARMACOTHER vol. 58, (1) 71-71.
10.1016/S0753-3322(03)00041-6
Cuzick J, DUFFY SW, Warren RML, Pinney E, Warwick J(2004). Effect of tamoxifen on women at increased risk of breast cancer. J Natl. Cancer Institute. vol. 96, 621-628.
CUZICK JM, Hamed H, O'neill C(2004). Genetic and other factors related to tamoxifen-associated venous thromboembolic. The American Journal of Oncology Review. vol. 3, 405-406.
CUZICK JM(2004). Screening for cervical cancer. Cervical Cancer: From Etiology to Prevention. T. E. Rohan & K. V. Shah (eds)., Kluwer Academic Publishers.
Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U et al.(2003). Management of women who test positive for high-risk types of human papillomavirus: the HART study. LANCET vol. 362, (9399) 1871-1876.
10.1016/S0140-6736(03)14955-0
Cuzick J(2003). Epidemiology of breast cancer - selected highlights. BREAST vol. 12, (6) 405-411.
10.1016/S0960-9776(03)00144-9
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J et al.(2003). The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG vol. 110, (12) 1099-1106.
10.1111/j.1471-0528.2003.02120.x
Cuzick J(2003). Treatment of DCIS--results from clinical trials. Surg Oncol vol. 12, (4) 213-219.
10.1016/j.suronc.2003.09.001
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group(2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer vol. 98, (9) 1802-1810.
10.1002/cncr.11745
Duggan C, Marriott K, Edwards R, Cuzick J(2003). Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J CLIN ONCOL vol. 21, (19) 3588-3593.
10.1200/JCO.2003.10.111
Cuzick J, O'Neill C, Howell T, Forbes J(2003). Anastrozole for ductal carcinoma in situ. LANCET vol. 362, (9386) 832-833.
10.1016/S0140-6736(03)14257-2
Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M et al.(2003). Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer vol. 39, (12) 1711-1717.
10.1016/s0959-8049(03)00392-7
Sasieni P, Cuzick J(2003). The UK breast-screening programme should start at age 47 years. LANCET vol. 362, (9379) 246-247.
10.1016/S0140-6736(03)13922-0
Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research, Ductal Carcinoma in situ Working Party et al.(2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet vol. 362, (9378) 95-102.
10.1016/s0140-6736(03)13859-7
Sasieni P, Adams J, Cuzick J(2003). Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. BRIT J CANCER vol. 89, (1) 88-93.
10.1038/sj.bjc.6600974
De Vries E, Boniol M, Severi G, Brandberg Y, Eggermont A, Ringborg U, Grivegnee A, Coebergh JW et al. (2003). Sunbed use in melanoma cases and controls in Europe: a European Union multicentre case-control study. BRITISH JOURNAL OF DERMATOLOGY. vol. 149, 87-88.
Warwick J, Pinney E, Warren RML, Duffy SW, Howell A, Wilson M, Cuzick J(2003). Breast density and breast cancer risk factors in a high-risk population. BREAST vol. 12, (1) 10-16.
10.1016/S0960-9776(02)00212-6
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P(2003). Overview of the main outcomes in breast-cancer prevention trials. LANCET vol. 361, (9354) 296-300.
10.1016/S0140-6736(03)12342-2
Cuzick J, Forbes J, Howell A, IBIS Investigators(2003). Tamoxifen for breast-cancer prevention - Reply. LANCET vol. 361, (9352) 178-178.
10.1016/S0140-6736(03)12212-X
Cuzick J (2003). Aromatase inhibitors in prevention - Data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second international breast cancer intervention study). TUMOR PREVENTION AND GENETICS. Editors: Senn, HJ, Morant, R, vol. 163, 96-103.
10.1007/978-3-642-55647-0_9
CUZICK JM(2003). Breast Cancer Prevention Trials. Evidence-Based Oncology. Williams C (Eds)., BMJ Publishing Group
CUZICK JM, Baum M, Houghton J(2003). Chapter 6. Design and statistical considerations. History and Advancement of Anastrozole in the treatment of Breast Cancer. Buzlar A and Baum M. (Eds)., Royal Society of Medicine Press Ltd (London),
CUZICK JM(2003). Chemoprevention of Breast Cancer. The American Journal of Oncology Review vol. 2, 319-321.
Sasieni P, CUZICK JM(2003). Epidemiology of gynaecological cancer. Gynaecology (3rd ed) Shaw RW, Soutter WP, Stanton SL (Eds)., Churchill Livingstone (London),
CUZICK JM(2003). Human Papilloma Screening for lower genital tract neoplasia. Lower Genital Tract Neoplasia. Maclean A, Singer A and Critchley H (Eds)., Royal College of Obstetricians and Gynaecology Press
Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, Singer A(2003). Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. J MED VIROL vol. 69, (1) 118-121.
10.1002/jmv.10257
CUZICK JM, Veronesi U, Boyle P, Ashley S, Powles T, Forbes J, Edwards R(2003). Overview of the main outcomes in breast cancer prevention trials. Obstet Gynae Survey vol. 58, (7) 463-465.
10.1097/01.ogx.0000074099.38382.13
Sauerbrei W, Schumacher M, Cuzick J, Jonat W, Kaufmann M (2003). Prognostic factors determine groups with different prognoses in pre- and perimenopausal women with estrogen receptor-positive, node-positive breast cancer treated with goserelin (Zoladex (R)) or CMF - results from the ZEBRA study. BREAST CANCER RESEARCH AND TREATMENT. vol. 82, S121-S121.
Wardle J, Williamson S, Sutton S, Biran A, McCaffery K, Cuzick J, Atkin W(2003). Psychological impact of colorectal cancer screening. HEALTH PSYCHOL vol. 22, (1) 54-59.
10.1037/0278-6133.22.1.54
CUZICK JM(2003). Vaccination against cervical cancer - trial boost hopes [Editorial]. Trends in Urology Gynaecology and Sexual Health vol. 8, 5-6.
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC et al.(2002). Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol vol. 20, (24) 4628-4635.
10.1200/JCO.2002.05.042
Locker G, Sainsbury R, Cuzick J, ATAC Trialists' Grp (2002). Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy. BREAST CANCER RESEARCH AND TREATMENT. vol. 76, S35-S35.
Kaufmann M, Jonat W, Blarney R, Cuzick J, Fogelman I, De Haes J, Namer M, Sauerbrei W et al. (2002). Updated survival results from the Zebra trial. BREAST CANCER RESEARCH AND TREATMENT. vol. 76, S73-S73.
Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Coates RJ, Liff JM et al.(2002). Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer vol. 87, (11) 1234-1245.
10.1038/sj.bjc.6600596
Ashton HA, Buxton MJ, Campbell HE, Day NE, Kim LG, Marteau TM, Scott RAP, Thompson SG et al.(2002). Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. BRIT MED J vol. 325, (7373) 1135-1138B.
10.1136/bmj.325.7373.1135
Cuzick J (2002). Prevention of breast cancer. EUROPEAN JOURNAL OF CANCER. vol. 38, S85-S86.
Cuzick J (2002). Rationale for a study testing aromatase inhibitors in prevention and DCIS. EUROPEAN JOURNAL OF CANCER. vol. 38, S81-S81.
Cuzick J (2002). Role of HPV testing in clinical practice. Virus Res. vol. 89, 263-269.
10.1016/s0168-1702(02)00194-6
Eccles DM, Dowsett M, Howell A, Evans G, Chapman K, Eeles R, Mackay J, Fallowfield L et al. (2002). The raloxifene plus zoladex (RAZOR) trial for breast cancer risk reduction. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. vol. 11, 1194S-1194S.
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A et al.(2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet vol. 360, (9336) 817-824.
10.1016/s0140-6736(02)09962-2
Eastell R, Hannon RA, Cuzick J, Clack G, Adams JE (2002). Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) study. JOURNAL OF BONE AND MINERAL RESEARCH. vol. 17, S165-S165.
Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, Todd IP(2002). The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology vol. 41, (3A) 59-81.
10.1046/j.1365-2559.2002.14861.x
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JGM, Sahmoud T, ATAC Trialists' Group(2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet vol. 359, (9324) 2131-2139.
10.1016/s0140-6736(02)09088-8
Cuzick J(2002). Breast cancer screening--time to move forward. Breast vol. 11, (3) 209-210.
10.1054/brst.2002.0439
Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JMA, Wardle J, UK Flexible Sigmoidoscopy Screenin(2002). Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. LANCET vol. 359, (9314) 1291-1300.
10.1016/S0140-6736(02)08268-5
Cuzick J(2002). Update on new studies in Europe. EUR J CANCER vol. 38, S44-S44.
10.1016/S0959-8049(02)80107-1
Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, Sherman ME, Stoler MH et al. (2002). Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer. vol. 96, 14-20.
10.1002/cncr.10317
Terry G, Ho L, Londesborough P, Cuzick J(2002). Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions. Br J Cancer vol. 86, (3) 376-381.
10.1038/sj.bjc.6600077
Sasieni PD, Adams J, Cuzick J(2002). Avoidance of premature death: a new definition for the proportion cured. J Cancer Epidemiol Prev vol. 7, (4) 165-171.
Sasieni P, Cuzick J(2002). Cervical cancer - Could HPV testing become the sole primary cervical screening test?. J MED SCREEN vol. 9, (2) 49-51.
10.1136/jms.9.2.49
Duffy SW, Cuzick J, Tabar L, Vitak B, Chen THH, Yen MF, Smith RA(2002). Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. J ROY STAT SOC C-APP vol. 51, 235-243.
10.1111/1467-9876.00266
Sasieni P, Cuzick J(2002). Could HPV testing become the sole primary cervical screening test?. J Med Screen vol. 9, (2) 49-51.
10.1136/jms.9.2.49
Cuzick J, International Breast Cancer Intervention Study (2001). A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials. Ann N Y Acad Sci. vol. 949, 123-133.
10.1111/j.1749-6632.2001.tb04010.x
Cuzick J, Sasieni P(2001). Natural history of cervical human papillomavirus. Lancet vol. 358, (9292) 1550-1551.
10.1016/S0140-6736(01)06602-8
Cuzick J(2001). Time to consider HPV testing in cervical screening. Ann Oncol vol. 12, (11) 1511-1514.
10.1023/a:1013117823929
Duffy SW, Cuzick J(2001). Let's talk about mammographic screening over again - response. BREAST vol. 10, (5) 450-451.
Bosch FX, Muñoz N, de Sanjosé S, Franco EL, Lowy DR, Schiffman M, Franceschi S, Kjaer SK et al.(2001). Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst vol. 93, (17) 1349-1350.
10.1093/jnci/93.17.1349
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A(2001). Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol vol. 65, (1) 155-162.
10.1002/jmv.2015.abs
Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A(2001). Fatal adenovirus type 7b infection in a child with Smith-Lemli-Opitz syndrome. Journal of Medical Virology vol. 65, (1) 66-69.
10.1002/jmv.2002
Dowsett M, Cuzick J, Howell A, Jackson I, ATAC Trialists' Group(2001). Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer vol. 85, (3) 317-324.
10.1054/bjoc.2001.1925
Cuzick J, George WD, Houghton J, DCIS Working Party(2001). UKCCCR trial of tamoxifen and/or radiotherapy for DCIS. BRIT J CANCER vol. 85, 2-2.
Cuzick J(2001). Is hormone replacement therapy safe for breast cancer patients?. J Natl Cancer Inst vol. 93, (10) 733-734.
10.1093/jnci/93.10.733
Sasieni P, Cuzick J(2001). Routine audit is an ethical requirement of screening. BMJ vol. 322, (7295)
10.1136/bmj.322.7295.1179
Cuzick J(2001). A strong law for weighted sums of I.I.D. random variables (vol 8, pg 625, 1995). J THEOR PROBAB vol. 14, (2) 605-605.
10.1023/A:1011132202003
Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J(2001). Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol vol. 19, (7) 1885-1892.
10.1200/JCO.2001.19.7.1885
Cuzick J(2001). Event-based analysis times for randomised clinical trials. BIOMETRIKA vol. 88, (1) 245-253.
10.1093/biomet/88.1.245
Szarewski A, Maddox P, Royston P, Jarvis M, Anderson M, Guillebaud J, Cuzick J(2001). The effect of stopping smoking on cervical Langerhans' cells and lymphocytes. BJOG vol. 108, (3) 295-303.
10.1111/j.1471-0528.2001.00074.x
Atkin WS, Edwards R, Wardle J, Northover JM, Sutton S, Hart AR, Williams CB, Cuzick J(2001). Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening. J Med Screen vol. 8, (3) 137-144.
10.1136/jms.8.3.137
Mackay J, Rogers C, Fielder H, Blamey R, Macmillan D, Boggis C, Brown J, Pharoah PD et al.(2001). Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer. J Epidemiol Biostat vol. 6, (5) 365-369.
10.1080/135952201753337086
Cuzick J(2001). HPV testing in cervical screening. Pharmacoepidemiol Drug Saf vol. 10, (1) 33-36.
10.1002/pds.558
De Nigris A, Paladini G, Duffy SW, Cuzick J(2001). Letter to the editor (multiple lettes) [1]. Breast vol. 10, (5) 450-451.
Cuzick J(2000). The classic approach. Cancer vol. 89, (11 SUPPL.) 2397-2398.
10.1002/1097-0142(20001201)89:11+<2397::aid-cncr14>3.3.co;2-t
Cuzick J, Howell A(2000). A brief review of the breast cancer prevention trials. European Journal of Cancer vol. 36, (SUPPL. 4)
10.1016/s0959-8049(00)00225-2
Cuzick J (2000). A brief review of the current breast cancer prevention trials and proposals for future trials. European Journal of Cancer. vol. 36, 1298-1302.
10.1016/S0959-8049(00)00106-4
Cuzick J, Terry G, Ho L, Monaghan J, Lopes A, Clarkson P, Duncan I(2000). Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. British Journal of Cancer vol. 82, (7) 1348-1352.
10.1054/bjoc.1999.1103
Cuzick J(2000). Future possibilities in the prevention of breast cancer - Breast cancer prevention trials. BREAST CANCER RES vol. 2, (4) 258-263.
10.1186/bcr66
Cuzick J(2000). Viruses and cancer. Journal of epidemiology and biostatistics vol. 5, (3) 143-152.
Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK et al.(1999). HPV testing in primary screening of older women. British Journal of Cancer vol. 81, (3) 554-558.
10.1038/sj.bjc.6690730
Cuzick J(1999). Screening for cancer: Future potential. European Journal of Cancer vol. 35, (5) 685-692.
10.1016/S0959-8049(99)00070-2
Cuzick J (1999). Once-only sigmoidoscopy. Annals of Oncology. vol. 10,
10.1093/annonc/10.suppl_6.S65
Cuzick J(1999). Screening for cancer: Future potential. European Journal of Cancer vol. 35, (14) 1925-1932.
10.1016/S0959-8049(99)00295-6
Cuzick J(1998). Screening. Cancer Surveys vol. 33, 345-354.
Hutchings O, Evans G, Fallowfield L, Cuzick J, Howell A(1998). Effect of early American results on patients in a tamoxifen prevention trial (IBIS) [3]. Lancet vol. 352, (9135)
10.1016/S0140-6736(05)60560-0
Cuzick J, Holland R, Barth V, Davies R, Faupel M, Fentiman I, Frischbier HJ, LaMarque JL et al.(1998). Electropotential measurements as a new diagnostic modality for breast cancer. Lancet vol. 352, (9125) 359-363.
10.1016/S0140-6736(97)10002-2
Holli K, Isola J, Cuzick J(1998). Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. Journal of Clinical Oncology vol. 16, (9) 3115-3120.
10.1200/JCO.1998.16.9.3115
Holli K, Isola J, Cuzick J(1997). Hormone replacement therapy and biological aggressiveness of breast cancer [3]. Lancet vol. 350, (9092) 1704-1705.
10.1016/S0140-6736(05)64308-5
Terry G, Ho L, Cuzick J(1997). Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. International Journal of Cancer vol. 73, (5) 651-655.
10.1002/(SICI)1097-0215(19971127)73:5<651::AID-IJC7>3.0.CO;2-W
Cuzick J(1997). The use of hormone replacement therapy for women with breast cancer: A trial in the advanced disease setting. Endocrine-Related Cancer vol. 4, (3) 281-283.
10.1677/erc.0.0040281
Odunsi K, Terry G, Linda HO, Bell J, Cuzick J, Ganesan TS(1996). Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. International Journal of Cancer vol. 67, (5) 595-602.
10.1002/(SICI)1097-0215(19960904)67:5<595::AID-IJC1>3.0.CO;2-P
Thirlaway K, Fallowfield L, Cuzick J(1996). The sexual activity questionnaire: A measure of women's sexual functioning. Quality of Life Research vol. 5, (1) 81-90.
10.1007/BF00435972
Cuzick J(1996). Chemoprevention of breast cancer with tamoxifen. IARC scientific publications (136) 95-109.
Londesborough P, Linda HO, Terry G, Cuzick J, Wheeler C, Singer A(1996). Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. International Journal of Cancer vol. 69, (5) 364-368.
10.1002/(sici)1097-0215(19961021)69:5<364::aid-ijc2>3.0.co;2-3
Cuzick J(1996). Medicinal drugs with hormonal activity as chemopreventive agents. IARC scientific publications (139) 99-114.
Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS(1995). Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia. Molecular medicine (Cambridge, Mass.) vol. 1, (2) 161-171.
10.1007/bf03401564
Cuzick J (1995). Human papillomavirus infection of the prostate. Cancer Surveys. vol. 23, 91-95.
Cuzick J, Zito R(1994). Genotoxicity of tamoxifen [1]. Journal of Experimental and Clinical Cancer Research vol. 13, (4) 417-418.
Terry G, Ho L, Szarewski A, Cuzick J(1994). Semiautomated detection of human papillomavirus DNA of high and low oncoaenic potential in cervical smears. Clinical Chemistry vol. 40, (10) 1890-1892.
King MM, Hollingsworth A, Cuzick J, Garner RC(1994). The detection of adducts in human cervix tissue dna using p-postlabelling: A study of the relationship with smoking history and oral contraceptive use. Carcinogenesis vol. 15, (5) 1097-1100.
10.1093/carcin/15.5.1097
Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M et al.(1994). Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. Journal of Clinical Oncology vol. 12, (3) 447-453.
10.1200/JCO.1994.12.3.447
Cuzick J, Mossman J, Stewart H(1994). Cooperative breast cancer trials organized by the United Kingdom co‐ordinating committee on cancer research. Cancer vol. 74, (3 S) 1160-1163.
10.1002/1097-0142(19940801)74:3+<1160::AID-CNCR2820741527>3.0.CO;2-Z
Maddox P, Szarewski A, Dyson J, Cuzick J(1994). Cytokeratin expression and acetowhite change in cervical epithelium. Journal of Clinical Pathology vol. 47, (1) 15-17.
10.1136/jcp.47.1.15
Cuzick J(1994). Multiple myeloma. Cancer Surveys vol. 19-20, 455-474.
Mansell ME, Ho L, Terry G, Singer A, Cuzick J(1994). Semi‐quantitative human papillomavirus DNA detection in the management of women with minor cytological abnormality. BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 101, (9) 807-809.
10.1111/j.1471-0528.1994.tb11952.x
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M(1994). Type-specific human papillomavirus dna in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. British Journal of Cancer vol. 69, (1) 167-171.
10.1038/bjc.1994.28
Bianchini F, Montesano R, Shuker DEG, Cuzick J, Wild CP(1993). Quantification of 7-methyldeoxyguanosine using immunoaffinity purification and HPLC with electrochemical detection. Carcinogenesis vol. 14, (8) 1677-1682.
10.1093/carcin/14.8.1677
Atkin WS, Cuzick J(1993). Screening for colorectal cancer. The Lancet vol. 341, (8861)
10.1016/0140-6736(93)90807-S
Atkin WS, Northover JMA, Cuzick J, Whynes DK(1993). Prevention of colorectal cancer by once-only sigmoidoscopy. The Lancet vol. 341, (8847) 736-740.
10.1016/0140-6736(93)90499-7
King MM, Cuzick J, Jenkins D, Routledge MN, Garner RC(1993). Immunoaffinity concentration of human lung DNA adducts using an anti-benzo[a]pyrene-diol-epoxide-DNA antibody. Analysis by <sup>32</sup>P-postlabelling or ELISA. Mutation Research/Environmental Mutagenesis and Related Subjects vol. 292, (2) 113-122.
10.1016/0165-1161(93)90138-P
Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C et al.(1993). Long term effects of tamoxifen. Biological Effects of Tamoxifen Working Party. European Journal of Cancer vol. 29, (1) 15-21.
10.1016/0959-8049(93)90568-Z
Cuzick J, Baum M, Paterson AHG, Neven P, Lowe DG, Shepherd JH, Nicholson RH(1992). Prevention of breast cancer. The Lancet vol. 340, (8834-8835) 1550-1552.
10.1016/0140-6736(92)92807-R
Jones MH, Singer A, Jenkins D, Cuzick J, Wolfendale MR, Usherwood MMD, Jones JJ, Balogun-Lynch C(1992). Mild cervical dyskaryosis: safety of cytological surveillance. The Lancet vol. 339, (8807) 1440-1443.
10.1016/0140-6736(92)92031-A
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M(1992). Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer. The Lancet vol. 339, (8799) 959-960.
10.1016/0140-6736(92)91532-D
Routledge MN, Garner RC, Jenkins D, Cuzick J(1992). <sup>32</sup>P-postlabelling analysis of DNA from human tissues. Mutation Research Letters vol. 282, (3) 139-145.
10.1016/0165-7992(92)90087-X
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M(1992). HPV in cervical smears [1]. Lancet vol. 340, (8811) 112-113.
10.1016/0140-6736(92)90431-2
Cuzick J(1992). Methodologic issues in the chemoprevention of breast cancer. Cancer detection and prevention vol. 16, (1) 81-85.
Jones MH, Jenkins D, Cuzick J, Wolfendale MR, Jones JJ, Balogun-Lynch C, Usherwood MM, Singer A(1992). Mild cervical dyskaryosis: Safety of cytological surveillance. Obstetrical and Gynecological Survey vol. 47, (11) 792-794.
10.1097/00006254-199211000-00020
Cuzick J, Berridge D, Whitehead J(1991). Mammographic dysplasia as entry criterion for breast cancer prevention trials. The Lancet vol. 337, (8751)
10.1016/0140-6736(91)92897-B
Szarewski A, Cuzick J(1991). Authors' reply. BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 98, (7) 741-743.
10.1111/j.1471-0528.1991.tb13475.x
Scholefield JH, Northover JMA, Cuzick J(1990). Anal cancer and marital status. British Journal of Cancer vol. 62, (2) 286-288.
10.1038/bjc.1990.279
Cuzick J, Singer A, De Stavola BL, Chomet J(1990). Case-control study of risk factors for cervical intraepithelial neoplasia in young women. European Journal of Cancer and Clinical Oncology vol. 26, (6) 684-690.
10.1016/0277-5379(90)90117-C
Cuzick J, Routledge MN, Jenkins D, Garner RC(1990). DNA adducts in different tissues of smokers and non‐smokers. International Journal of Cancer vol. 45, (4) 673-678.
10.1002/ijc.2910450417
CUZICK J(1990). International Time Trends for Multiple Myeloma. Annals of the New York Academy of Sciences vol. 609, (1) 205-214.
10.1111/j.1749-6632.1990.tb32068.x
Garner RC, Cuzick J, Jenkins D, Phillips DH, Hewer A, King MM, Routledge MN(1990). Linear relationship between DNA adducts in human lung and cigarette smoking. IARC scientific publications (104) 421-426.
Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan ICM(1990). Long‐term prognostic value of serum β<inf>2</inf> microglobulin in myelomatosis. British Journal of Haematology vol. 75, (4) 506-510.
10.1111/j.1365-2141.1990.tb07790.x
Cuzick J(1990). Overview of adjuvant radiotherapy for breast cancer. Progress in clinical and biological research vol. 354 B, 227-232.
Cuzick J, de Stavolal BL, Russell MJ, Thomas BS(1990). Vitamin A, vitamin E and the risk of cervical intraepithelial neoplasia. British Journal of Cancer vol. 62, (4) 651-652.
10.1038/bjc.1990.348
Cuzick J, De Stavola BL(1989). Autoimmune disorders and multiple meyloma. International Journal of Epidemiology vol. 18, (1)
10.1093/ije/18.1.283
Cuzick J, de Stavola B, McCance D, Ho TH, Tan G, Cheng H, Chew SY, Salmon YM(1989). A case-control study of cervix cancer in Singapore. British Journal of Cancer vol. 60, (2) 238-243.
10.1038/bjc.1989.261
BARTON SE, SINGER A, JENKINS D, HOLLINGWORTH A, CUZICK J(1989). An explanation for the problem of false‐negative cervical smears. BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 96, (4) 482-485.
10.1111/j.1471-0528.1989.tb02428.x
Cuzick J(1989). Overview of adjuvant radiotherapy for breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 115, 220-225.
10.1007/978-3-642-83337-3_32
Cuzick J, Babiker AG(1989). Pancreatic cancer, alcohol, diabetes mellitus and gall‐bladder disease. International Journal of Cancer vol. 43, (3) 415-421.
10.1002/ijc.2910430312
Barton SE, Hollingworth A, Maddox PH, Edwards R, Cuzick J, McCance DJ, Jenkins D, Singer A(1989). Possible cofactors in the etiology of cervical intraepithelial neoplasia. An immunopathologic study. Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 34, (9) 613-616.
Barton SE, Jenkins D, Cuzick J, Maddox PH, Edwards R, Singer A(1988). EFFECT OF CIGARETTE SMOKING ON CERVICAL EPITHELIAL IMMUNITY: A MECHANISM FOR NEOPLASTIC CHANGE?. The Lancet vol. 332, (8612) 652-654.
10.1016/S0140-6736(88)90469-2
Havelock C, Edwards R, Cuzick J, Chamberlain J(1988). The organization of cervical screening in general practice. Journal of the Royal College of General Practitioners vol. 38, (310) 207-211.
Cuzick J(1988). Cervical screening. British Journal of Hospital Medicine vol. 39, (4)
Cuzick J, De Stavola B(1988). Multiple myeloma a case-control study. British Journal of Cancer vol. 57, (5) 516-520.
10.1038/bjc.1988.118
Cuzick J(1988). Overview of adjuvant radiotherapy for breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 111, 105-107.
10.1007/978-3-642-83419-6_14
Cuzick J, Stewart HJ, Peto R, Baum M, Fisher B, Host H, Lythgoe JP, Ribeiro G et al.(1988). Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer vol. 111, 108-129.
10.1007/978-3-642-83419-6_15
CAMPION MJ, BROWN JR, MCCANCE DJ, ATIA W, EDWARDS R, CUZICK J, SINGER A(1988). Psychosexual trauma of an abnormal cervical smear. BJOG: An International Journal of Obstetrics &amp; Gynaecology vol. 95, (2) 175-181.
10.1111/j.1471-0528.1988.tb06848.x
MacLennan ICM, Kelly K, Crockson RA, Cooper EH, Cuzick J, Chapman C(1988). Results of the mrc myelomatosis trials for patients entered since 1980. Hematological Oncology vol. 6, (2) 145-158.
10.1002/hon.2900060215
Shih WJ, Cuzick J(1988). Testing in case-control studies with ordinal exposure variables. Biometrics vol. 44, (3) 901-905.
10.2307/2531602
Cuzick J, Boyle P(1988). Trends in cervix cancer mortality. Cancer surveys vol. 7, (3) 417-439.
Fentiman IS, Balkwill FR, Cuzick J, Hayward JL, Rubens RD(1987). A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence. European Journal of Surgical Oncology vol. 13, (5) 425-428.
Hollingworth A, Barton SE, Jenkins D, Cuzick J, Singer A(1987). Colposcopy of women with cervical HPV type 16 infection but normal cytology. Lancet vol. 2, (8568)
10.1016/s0140-6736(87)91573-x
Cuzick J, Stewart H, Peto R, Fisher B, Kaae S, Johansen H, Lythgoe JP, Prescott RJ(1987). Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treatment Reports vol. 71, (1) 7-14.
Cuzick J, Stewart H, Peto R, Baum M, Fisher B, Host H, Lythgoe JP, Ribeiro G et al.(1987). Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treatment Reports vol. 71, (1) 15-29.
Goh HS, Jass JR, Atkin WS, Cuzick J, Northover JMA(1987). Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis. International Journal of Colorectal Disease vol. 2, (1) 17-21.
10.1007/BF01648992
Cuzick J, Erskine S, Edelman D, Galton DAG(1987). A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis: A report to the medical research council’s working party on leukaemia in adults. British Journal of Cancer vol. 55, (5) 523-529.
10.1038/bjc.1987.107
Campion MJ, Cuzick J, McCance DJ, Singer A(1987). Progressive potential of mild cervical atypia: Prospective cytological, colposcopic, and virologic study. Obstetrical and Gynecological Survey vol. 42, (4) 260-262.
10.1097/00006254-198704000-00021
Campion MJ, Cuzick J, McCance DJ, Singer A(1986). PROGRESSIVE POTENTIAL OF MILD CERVICAL ATYPIA: PROSPECTIVE CYTOLOGICAL, COLPOSCOPIC, AND VIROLOGICAL STUDY. The Lancet vol. 328, (8501) 237-240.
10.1016/S0140-6736(86)92067-2
Cuzick J, Wang DY, Bulbrook RD(1986). THE PREVENTION OF BREAST CANCER. The Lancet vol. 327, (8472) 83-86.
10.1016/S0140-6736(86)90729-4
JASS JR, ATKIN WS, CUZICK J, BUSSEY HJR, MORSON BC, NORTHOVER JMA, TODD IP(1986). The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology vol. 10, (5) 437-459.
10.1111/j.1365-2559.1986.tb02497.x
Bodmer W, Chamberlain J, Cook G, Cuzick J, Draper G, Erskine S, Fisher H, Griffiths R et al.(1986). The management of a cervical screening programme: A statement (October 1985). Journal of Public Health (United Kingdom) vol. 8, (3) 179-184.
10.1093/oxfordjournals.pubmed.a043852
Clayton D, Cuzick J(1985). EM ALGORITHM FOR COX'S REGRESSION MODEL USING GLIM. Journal of the Royal Statistical Society. Series C: Applied Statistics vol. 34, (2) 148-156.
Cuzick J, Baum M(1985). TAMOXIFEN AND CONTRALATERAL BREAST CANCER. The Lancet vol. 326, (8449)
10.1016/S0140-6736(85)90338-1
Cuzick J(1985). A method for analysing case-control studies with ordinal exposure variables. Biometrics vol. 41, (3) 609-621.
10.2307/2531281
Cuzick J(1985). A wilcoxon‐type test for trend. Statistics in Medicine vol. 4, (1) 87-90.
10.1002/sim.4780040112
Cuzick J(1985). Searching for clusters and associations in cancer epidemiology. Leukemia Research vol. 9, (6) 669-670.
10.1016/0145-2126(85)90272-3
Cuzick J, Cooper EH, MacLennan ICM(1985). The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis. British Journal of Cancer vol. 52, (1) 1-6.
10.1038/bjc.1985.140
Cuzick J, Cooper EH, MacLennan ICM(1985). The prognostic value of serum β2 microglobulin compared with other presentation features in myelomatosis. (A report to the Medical Research Council's Working Party on leukaemia in adults). British Journal of Cancer vol. 52, (1) 1-6.
10.1038/bjc.1985.140
Cuzick J(1984). A review of semi-parametric models for life histories. IMA Journal of Mathematics Applied in Medicine and Biology vol. 1, (4) 323-332.
10.1093/imammb/1.4.323
Fentiman IS, Cuzick J, Millis RR, Hayward JL(1984). Which patients are cured of breast cancer?. British Medical Journal vol. 289, (6452) 1108-1111.
10.1136/bmj.289.6452.1108
Cuzick J, Harris R, Mortimer PS(1984). PALMAR KERATOSES AND CANCERS OF THE BLADDER AND LUNG. The Lancet vol. 323, (8376) 530-533.
10.1016/S0140-6736(84)90931-0
Turesson I, Zettervall O, Cuzick J, Waldenstrom JG, Velez R(1984). Comparison of Trends in the Incidence of Multiple Myeloma in Malmö, Sweden, and Other Countries, 1950–1979. New England Journal of Medicine vol. 310, (7) 421-424.
10.1056/NEJM198402163100703
Cuzick J(1984). A review of semi-parametric models for life histories. Mathematical Medicine and Biology vol. 1, (4) 323-332.
10.1093/imammb/1.4.323
Chaudary MA, Millis RR, Hoskins EOL, Halder M, Bulbrook RD, Cuzick J, Hayward JL(1984). Bilateral primary breast cancer: A prospective study of disease incidence. British Journal of Surgery vol. 71, (9) 711-714.
10.1002/bjs.1800710924
Cuzick J, Bulstrode JC, Stratton I, Thomas BS, Bulbrook RD, Hayward JL(1983). A prospective study of urinary androgen levels and ovarian cancer. International Journal of Cancer vol. 32, (6) 723-726.
10.1002/ijc.2910320611
Goldstein IF, Cuzick J(1983). Daily patterns of asthma in New York City and New Orleans: An epidemiologic investigation. Environmental Research vol. 30, (1) 211-223.
10.1016/0013-9351(83)90181-0
Cuzick J, Velez R, Doll R(1983). International variations and temporal trends in mortality from multiple myeloma. International Journal of Cancer vol. 32, (1) 13-19.
10.1002/ijc.2910320104
Mortimer PS, Harris R, Dawber RPR, Cuzick J(1983). Palmar keratoses and internal malignancy. British Journal of Dermatology vol. 109, (Suppl. 24) 21-22.
10.1111/j.1365-2133.1983.tb11564.x
Leonard RCF, Cuzick J, MacLennan ICM, Vanhegan RI, Mackie PH, McCormick CV, Knight F, Laing AH et al.(1983). Prognostic factors in non-Hodgkin's lymphoma: The importance of symptomatic stage as an adjunct to the Kiel histopathological classification. British Journal of Cancer vol. 47, (1) 91-102.
10.1038/bjc.1983.11
Cuzick J(1982). Multiple points of a Gaussian vector field. Zeitschrift für Wahrscheinlichkeitstheorie und Verwandte Gebiete vol. 61, (4) 431-436.
10.1007/BF00531614
Cuzick J(1982). The assessment of subgroups in clinical trials. Experientia. Supplementum vol. 41, 224-235.
Cuzick J(1982). Rank tests for association with right censored data. Biometrika vol. 69, (2) 351-364.
10.1093/biomet/69.2.351
Lavecchia C, Franceschi S, Cuzick J(1982). ALCOHOL AND BREAST CANCER. The Lancet vol. 319, (8272)
10.1016/S0140-6736(82)91775-5
Velez R, Beral V, Cuzick J(1982). Increased trends of multiple myeloma mortality in England and Wales: Are the changes real?. Journal of the National Cancer Institute vol. 69, (2) 387-392.
Peckham MJ, Tobias JS, Baum M, Berstock DA, Bullimore JA, Cuzick J, Durrant K, Faulder C et al.(1982). Letters to the editor. British Journal of Cancer vol. 46, (6)
10.1038/bjc.1982.319
Buckman R, Cuzick J, Galton DAG(1982). Long‐term survival in myelomatosis; A REPORT TO THE MRC WORKING PARTY ON LEUKAEMIA IN ADULTS. British Journal of Haematology vol. 52, (4) 589-599.
10.1111/j.1365-2141.1982.tb03935.x
Cuzick J, Evans S, Gillman M, Price Evans DA(1982). Medicinal arsenic and internal malignancies. British Journal of Cancer vol. 45, (6) 904-911.
10.1038/bjc.1982.143
Goldstein IF, Cuzick J(1981). Application of a time-space clustering methodology to the assessment of acute environmental effects on respiratory illnesses. Reviews on Environmental Health vol. 3, (3) 259-275.
Cuzick J(1981). THYROID DISEASE AND BREAST CANCER. The Lancet vol. 317, (8215)
10.1016/S0140-6736(81)91936-X
Cuzick J(1981). Radiation-Induced Myelomatosis. New England Journal of Medicine vol. 304, (4) 204-210.
10.1056/NEJM198101223040404
Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hayward JL, Millis RR, Cuzick J(1981). A prospective study of plasma prolactin levels and subsequent risk of breast cancer. International Journal of Cancer vol. 28, (6) 673-676.
10.1002/ijc.2910280603
Cuzick J, Lindgren G(1980). Frequency estimation from crossings of an unknown level. Biometrika vol. 67, (1) 65-72.
10.1093/biomet/67.1.65
Cuzick J(1980). The Hausdorff dimension of the level sets of a Gaussian vector field. Zeitschrift für Wahrscheinlichkeitstheorie und Verwandte Gebiete vol. 51, (3) 287-290.
10.1007/BF00587354
Leonard RCF, MacLennan ICM, Smart Y, Vanhegan RI, Cuzick J(1979). Light chain isotype‐associated suppression of normal plasma cell numbers in patients with multiple myeloma. International Journal of Cancer vol. 24, (4) 385-393.
10.1002/ijc.2910240402
Return to top